TheMysTrader的个人主页 - 老虎社区

TheMysTrader

TheMysTrader

暂无个人介绍

IP属地：未知

11关注

4粉丝

0主题

0勋章

2021-11-29

Will tesla 🚀 to a whole new level?

Tesla stock rallied nearly 3% in premarket trading<blockquote>特斯拉股价在盘前交易中上涨近3%</blockquote>

2021-11-27

$Sea Ltd(SE)$ awww where's the last hr sales

2021-11-05

Buy the slid wheee

抱歉，原内容已删除

2021-11-05

Will Pfizer for once pfi(fly) up to the moon? [财迷]

Pfizer rose over 9% in premarket trading as its antiviral pill cut risk of severe COVID-19 by 89%<blockquote>辉瑞(Pfizer)在盘前交易中上涨超过9%，其抗病毒药物将严重COVID-19的风险降低了89%</blockquote>

2021-11-05

Omg that's good news!

Pfizer rose over 9% in premarket trading as its antiviral pill cut risk of severe COVID-19 by 89%<blockquote>辉瑞(Pfizer)在盘前交易中上涨超过9%，其抗病毒药物将严重COVID-19的风险降低了89%</blockquote>

2021-10-21

Will $Tesla Motors(TSLA)$hit 900 alike earlier part of the year?

2021-06-24

Wow

抱歉，原内容已删除

2021-06-24

Bbtea ❤️

Bubble Tea Chain Raises $656 Million in Hong Kong IPO<blockquote>珍珠奶茶连锁店香港IPO融资6.56亿美元</blockquote>

2021-06-17

Wow[得意]

抱歉，原内容已删除

2021-06-17

Interesting

抱歉，原内容已删除

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3574940915326235","uuid":"3574940915326235","gmtCreate":1611848582544,"gmtModify":1638180009533,"name":"TheMysTrader","pinyin":"themystrader","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/08abc512620038ac153ab0bf62705216","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":4,"headSize":11,"tweetSize":10,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"35ec162348d5460f88c959321e554969-1","templateUuid":"35ec162348d5460f88c959321e554969","name":"精英交易员","description":"证券或期货账户累计交易次数达到30次","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.08.11","exceedPercentage":"60.62%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.06.15","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":600554198,"gmtCreate":1638178262115,"gmtModify":1638178262281,"author":{"id":"3574940915326235","authorId":"3574940915326235","name":"TheMysTrader","avatar":"https://static.tigerbbs.com/08abc512620038ac153ab0bf62705216","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574940915326235","idStr":"3574940915326235"},"themes":[],"htmlText":"Will tesla 🚀 to a whole new level?","listText":"Will tesla 🚀 to a whole new level?","text":"Will tesla 🚀 to a whole new level?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/600554198","repostId":"1180553445","repostType":4,"repost":{"id":"1180553445","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638177356,"share":"https://www.laohu8.com/m/news/1180553445?lang=zh_CN&edition=full","pubTime":"2021-11-29 17:15","market":"us","language":"en","title":"Tesla stock rallied nearly 3% in premarket trading<blockquote>特斯拉股价在盘前交易中上涨近3%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1180553445","media":"Tiger Newspress","summary":"Tesla stock rallied nearly 3% in premarket trading as it to start production in Germany in December,","content":"<p>Tesla stock rallied nearly&nbsp;3% in premarket trading&nbsp;as&nbsp;it to start production in Germany in December,according to&nbsp;Automobilwoche.</p><p><blockquote>据Automobilwoche报道，特斯拉股价在盘前交易中上涨近3%，该公司将于12月在德国开始生产。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/c924dd7ad062e13f25605d196e86462b\" tg-width=\"853\" tg-height=\"619\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p> Tesla Inc. will launch its overdue German production operations in December, Automobilwoche reported, estimating as many as 30,000 vehicles will be manufactured there in the first half of 2022.</p><p><blockquote>据Automobilwoche报道，特斯拉公司将于12月启动其迟来的德国生产业务，预计2022年上半年德国将生产多达30,000辆汽车。</blockquote></p><p> Production was to have begun in July but was delayed because the company hadn’t received environmental clearance. Local regulators are expected to grant the necessary permits within days, the magazine said, without reporting where it received its information.</p><p><blockquote>生产原定于7月开始，但由于该公司尚未获得环境许可而被推迟。该杂志称，当地监管机构预计将在几天内授予必要的许可，但没有报告从哪里收到信息。</blockquote></p><p> Five units of Model Y have already been completed at the Gigafactory near Berlin, though not on the production line. In January, serial production will start with 1,000 cars per week and gradually increase, according to Automobilwoche.</p><p><blockquote>柏林附近的超级工厂已经完成了五台Model Y，但尚未上生产线。据Automobilwoche称，1月份，批量生产将从每周1,000辆汽车开始，并逐渐增加。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tesla stock rallied nearly 3% in premarket trading<blockquote>特斯拉股价在盘前交易中上涨近3%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTesla stock rallied nearly 3% in premarket trading<blockquote>特斯拉股价在盘前交易中上涨近3%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-11-29 17:15</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Tesla stock rallied nearly&nbsp;3% in premarket trading&nbsp;as&nbsp;it to start production in Germany in December,according to&nbsp;Automobilwoche.</p><p><blockquote>据Automobilwoche报道，特斯拉股价在盘前交易中上涨近3%，该公司将于12月在德国开始生产。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/c924dd7ad062e13f25605d196e86462b\" tg-width=\"853\" tg-height=\"619\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p> Tesla Inc. will launch its overdue German production operations in December, Automobilwoche reported, estimating as many as 30,000 vehicles will be manufactured there in the first half of 2022.</p><p><blockquote>据Automobilwoche报道，特斯拉公司将于12月启动其迟来的德国生产业务，预计2022年上半年德国将生产多达30,000辆汽车。</blockquote></p><p> Production was to have begun in July but was delayed because the company hadn’t received environmental clearance. Local regulators are expected to grant the necessary permits within days, the magazine said, without reporting where it received its information.</p><p><blockquote>生产原定于7月开始，但由于该公司尚未获得环境许可而被推迟。该杂志称，当地监管机构预计将在几天内授予必要的许可，但没有报告从哪里收到信息。</blockquote></p><p> Five units of Model Y have already been completed at the Gigafactory near Berlin, though not on the production line. In January, serial production will start with 1,000 cars per week and gradually increase, according to Automobilwoche.</p><p><blockquote>柏林附近的超级工厂已经完成了五台Model Y，但尚未上生产线。据Automobilwoche称，1月份，批量生产将从每周1,000辆汽车开始，并逐渐增加。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1180553445","content_text":"Tesla stock rallied nearly 3% in premarket trading as it to start production in Germany in December,according to Automobilwoche.\n\nTesla Inc. will launch its overdue German production operations in December, Automobilwoche reported, estimating as many as 30,000 vehicles will be manufactured there in the first half of 2022.\nProduction was to have begun in July but was delayed because the company hadn’t received environmental clearance. Local regulators are expected to grant the necessary permits within days, the magazine said, without reporting where it received its information.\nFive units of Model Y have already been completed at the Gigafactory near Berlin, though not on the production line. In January, serial production will start with 1,000 cars per week and gradually increase, according to Automobilwoche.","news_type":1,"symbols_score_info":{"TSLA":0.9}},"isVote":1,"tweetType":1,"viewCount":2001,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":877561413,"gmtCreate":1637944348124,"gmtModify":1637944348124,"author":{"id":"3574940915326235","authorId":"3574940915326235","name":"TheMysTrader","avatar":"https://static.tigerbbs.com/08abc512620038ac153ab0bf62705216","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574940915326235","idStr":"3574940915326235"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SE\">$Sea Ltd(SE)$</a>&nbsp;awww where's the last hr sales","listText":"<a href=\"https://laohu8.com/S/SE\">$Sea Ltd(SE)$</a>&nbsp;awww where's the last hr sales","text":"$Sea Ltd(SE)$ awww where's the last hr sales","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/877561413","isVote":1,"tweetType":1,"viewCount":2308,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":846711921,"gmtCreate":1636113379725,"gmtModify":1636113503105,"author":{"id":"3574940915326235","authorId":"3574940915326235","name":"TheMysTrader","avatar":"https://static.tigerbbs.com/08abc512620038ac153ab0bf62705216","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574940915326235","idStr":"3574940915326235"},"themes":[],"htmlText":"Buy the slid wheee","listText":"Buy the slid wheee","text":"Buy the slid wheee","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/846711921","repostId":"1136485403","repostType":2,"isVote":1,"tweetType":1,"viewCount":2140,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":846797989,"gmtCreate":1636112138356,"gmtModify":1636112280599,"author":{"id":"3574940915326235","authorId":"3574940915326235","name":"TheMysTrader","avatar":"https://static.tigerbbs.com/08abc512620038ac153ab0bf62705216","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574940915326235","idStr":"3574940915326235"},"themes":[],"htmlText":"Will Pfizer for once pfi(fly) up to the moon?&nbsp;[财迷]&nbsp;","listText":"Will Pfizer for once pfi(fly) up to the moon?&nbsp;[财迷]&nbsp;","text":"Will Pfizer for once pfi(fly) up to the moon? [财迷]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/846797989","repostId":"1168526565","repostType":2,"repost":{"id":"1168526565","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1636109309,"share":"https://www.laohu8.com/m/news/1168526565?lang=zh_CN&edition=full","pubTime":"2021-11-05 18:48","market":"us","language":"en","title":"Pfizer rose over 9% in premarket trading as its antiviral pill cut risk of severe COVID-19 by 89%<blockquote>辉瑞(Pfizer)在盘前交易中上涨超过9%，其抗病毒药物将严重COVID-19的风险降低了89%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1168526565","media":"Tiger Newspress","summary":"A trial of Pfizer Inc's experimental antiviral pill for COVID-19 was stopped early after the drug wa","content":"<p>A trial of Pfizer Inc's experimental antiviral pill for COVID-19 was stopped early after the drug was shown to cut by 89% the chances of hospitalization or death for adults at risk of developing severe disease, the company said on Friday.</p><p><blockquote>辉瑞公司周五表示，该公司针对COVID-19的实验性抗病毒药物的试验提前停止，此前该药物被证明可以将有严重疾病风险的成年人住院或死亡的几率降低89%。</blockquote></p><p> The results appear to surpass those seen with Merck &amp; Co Inc's pill molnupiravir, which was shown last month to halve the likelihood of dying or being hospitalized for COVID-19 patients also at high risk of serious illness.</p><p><blockquote>这一结果似乎超过了默克公司(Merck&amp;Co Inc.)的药物molnupiravir的结果，该药物上个月被证明可以将同样具有严重疾病高风险的COVID-19患者死亡或住院的可能性减半。</blockquote></p><p> Full trial data is not yet available from either company.</p><p><blockquote>两家公司都尚未提供完整的试验数据。</blockquote></p><p> Pfizer said it plans to submit interim trial results for its pill, which is given in combination with an older antiviral called ritonavir, to the U.S. Food and Drug Administration as part of the emergency use application it opened in October.</p><p><blockquote>辉瑞表示，计划向美国提交其药物的中期试验结果，该药物与一种名为利托那韦的旧抗病毒药物联合使用。食品和药物管理局作为其10月份开放的紧急使用申请的一部分。</blockquote></p><p> The combination treatment, which will have the brand name Paxlovid, consists of three pills given twice daily.</p><p><blockquote>这种联合治疗的品牌名称为Paxlovid，包括每天两次服用三粒药丸。</blockquote></p><p> The planned analysis of 1,219 patients in Pfizer's study looked at hospitalizations or deaths among people diagnosed with mild to moderate COVID-19 with at least one risk factor for developing severe disease, such as obesity or older age.</p><p><blockquote>辉瑞研究中计划对1,219名患者进行分析，研究了被诊断患有轻度至中度COVID-19且至少有一种发展为严重疾病的风险因素（如肥胖或年龄较大）的人的住院或死亡情况。</blockquote></p><p> It found that 0.8% of those given Pfizer's drug within three days of symptom onset were hospitalized and none had died by 28 days after treatment. That compared with a hospitalization rate of 7% for placebo patients. There were also seven deaths in the placebo group.</p><p><blockquote>研究发现，在症状出现后三天内服用辉瑞药物的患者中，有0.8%住院治疗，没有人在治疗后28天内死亡。相比之下，安慰剂患者的住院率为7%。安慰剂组也有7例死亡。</blockquote></p><p> Rates were similar for patients treated within five days of symptoms - 1% of the treatment group was hospitalized, compared with 6.7% for the placebo group, which included 10 deaths.</p><p><blockquote>在出现症状5天内接受治疗的患者的比率相似——治疗组1%住院，而安慰剂组为6.7%，其中包括10例死亡。</blockquote></p><p> Antivirals need to be given as early as possible, before an infection takes hold, in order to be most effective. Merck tested its drug within five days of symptom onset.</p><p><blockquote>为了最有效，需要在感染发生之前尽早给予抗病毒药物。默克公司在症状出现后五天内测试了其药物。</blockquote></p><p> \"We saw that we did have high efficacy, even if it was five days after a patient has been treated ... people might wait a couple of days before getting a test or something, and this means that we have time to treat people and really provide a benefit from a public health perspective,\" Annaliesa Anderson, head of the Pfizer program, told Reuters.</p><p><blockquote>“我们发现我们确实具有很高的疗效，即使是在患者接受治疗五天后……人们可能会等待几天才能进行测试或其他事情，这意味着我们有时间治疗人们并从公共卫生的角度来看确实提供了好处，”辉瑞项目负责人安娜莉莎·安德森告诉路透社。</blockquote></p><p> The company did not detail side effects of the treatment, but said adverse events happened in about 20% of both treatment and placebo patients.</p><p><blockquote>该公司没有详细说明治疗的副作用，但表示约20%的治疗和安慰剂患者发生了不良事件。</blockquote></p><p> \"These data suggest that our oral antiviral candidate, if approved by regulatory authorities, has the potential to save patients’ lives, reduce the severity of COVID-19 infections, and eliminate up to nine out of ten hospitalizations,” Pfizer Chief Executive Albert Bourla said in a statement.</p><p><blockquote>辉瑞首席执行官Albert Bourla表示：“这些数据表明，我们的口服抗病毒候选药物如果获得监管机构的批准，有可能挽救患者的生命，降低COVID-19感染的严重程度，并消除多达十分之九的住院治疗。”在一份声明中说。</blockquote></p><p> Infectious disease experts stress that preventing COVID-19 through wide use of vaccines remains the best way to control the pandemic, but only 58% of Americans are fully vaccinated and access in many parts of the world is limited.</p><p><blockquote>传染病专家强调，通过广泛使用疫苗来预防新冠肺炎仍然是控制疫情的最佳方式，但只有58%的美国人完全接种了疫苗，世界许多地区的疫苗接种有限。</blockquote></p><p> Pfizer's drug, part of a class known as protease inhibitors, is designed to block an enzyme the coronavirus needs in order to multiply.</p><p><blockquote>辉瑞的药物是蛋白酶抑制剂类药物的一部分，旨在阻断冠状病毒繁殖所需的酶。</blockquote></p><p> Merck's molnupiravir has a different mechanism of action designed to introduce errors into the genetic code of the virus. Merck has already sold millions of courses of the treatment, which was approved this week by U.K. regulators, to the United States, the U.K. and others.</p><p><blockquote>默克公司的molnupiravir具有不同的作用机制，旨在将错误引入病毒的遗传密码。默克公司已向美国、英国和其他国家出售了数百万个疗程的治疗药物，该药物本周获得了英国监管机构的批准。</blockquote></p><p> Britain said earlier this month it had secured 250,000 courses of Pfizer's antiviral.</p><p><blockquote>英国本月早些时候表示，已获得25万个疗程的辉瑞抗病毒药物。</blockquote></p><p> Pfizer is also studying whether its pill could be used by people without risk factors for serious COVID-19 as well as to prevent coronavirus infection in people exposed to the virus.</p><p><blockquote>辉瑞还在研究其药物是否可以被没有严重新冠肺炎风险因素的人使用，以及预防接触该病毒的人感染冠状病毒。</blockquote></p><p> Its&nbsp;shares&nbsp;rose&nbsp;over&nbsp;9%&nbsp;in&nbsp;premarket&nbsp;trading.<img src=\"https://static.tigerbbs.com/190a24394aa60d689cf29552569f5e20\" tg-width=\"774\" tg-height=\"567\" width=\"100%\" height=\"auto\"></p><p><blockquote>其股价在盘前交易中上涨超过9%。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer rose over 9% in premarket trading as its antiviral pill cut risk of severe COVID-19 by 89%<blockquote>辉瑞(Pfizer)在盘前交易中上涨超过9%，其抗病毒药物将严重COVID-19的风险降低了89%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer rose over 9% in premarket trading as its antiviral pill cut risk of severe COVID-19 by 89%<blockquote>辉瑞(Pfizer)在盘前交易中上涨超过9%，其抗病毒药物将严重COVID-19的风险降低了89%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-11-05 18:48</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>A trial of Pfizer Inc's experimental antiviral pill for COVID-19 was stopped early after the drug was shown to cut by 89% the chances of hospitalization or death for adults at risk of developing severe disease, the company said on Friday.</p><p><blockquote>辉瑞公司周五表示，该公司针对COVID-19的实验性抗病毒药物的试验提前停止，此前该药物被证明可以将有严重疾病风险的成年人住院或死亡的几率降低89%。</blockquote></p><p> The results appear to surpass those seen with Merck &amp; Co Inc's pill molnupiravir, which was shown last month to halve the likelihood of dying or being hospitalized for COVID-19 patients also at high risk of serious illness.</p><p><blockquote>这一结果似乎超过了默克公司(Merck&amp;Co Inc.)的药物molnupiravir的结果，该药物上个月被证明可以将同样具有严重疾病高风险的COVID-19患者死亡或住院的可能性减半。</blockquote></p><p> Full trial data is not yet available from either company.</p><p><blockquote>两家公司都尚未提供完整的试验数据。</blockquote></p><p> Pfizer said it plans to submit interim trial results for its pill, which is given in combination with an older antiviral called ritonavir, to the U.S. Food and Drug Administration as part of the emergency use application it opened in October.</p><p><blockquote>辉瑞表示，计划向美国提交其药物的中期试验结果，该药物与一种名为利托那韦的旧抗病毒药物联合使用。食品和药物管理局作为其10月份开放的紧急使用申请的一部分。</blockquote></p><p> The combination treatment, which will have the brand name Paxlovid, consists of three pills given twice daily.</p><p><blockquote>这种联合治疗的品牌名称为Paxlovid，包括每天两次服用三粒药丸。</blockquote></p><p> The planned analysis of 1,219 patients in Pfizer's study looked at hospitalizations or deaths among people diagnosed with mild to moderate COVID-19 with at least one risk factor for developing severe disease, such as obesity or older age.</p><p><blockquote>辉瑞研究中计划对1,219名患者进行分析，研究了被诊断患有轻度至中度COVID-19且至少有一种发展为严重疾病的风险因素（如肥胖或年龄较大）的人的住院或死亡情况。</blockquote></p><p> It found that 0.8% of those given Pfizer's drug within three days of symptom onset were hospitalized and none had died by 28 days after treatment. That compared with a hospitalization rate of 7% for placebo patients. There were also seven deaths in the placebo group.</p><p><blockquote>研究发现，在症状出现后三天内服用辉瑞药物的患者中，有0.8%住院治疗，没有人在治疗后28天内死亡。相比之下，安慰剂患者的住院率为7%。安慰剂组也有7例死亡。</blockquote></p><p> Rates were similar for patients treated within five days of symptoms - 1% of the treatment group was hospitalized, compared with 6.7% for the placebo group, which included 10 deaths.</p><p><blockquote>在出现症状5天内接受治疗的患者的比率相似——治疗组1%住院，而安慰剂组为6.7%，其中包括10例死亡。</blockquote></p><p> Antivirals need to be given as early as possible, before an infection takes hold, in order to be most effective. Merck tested its drug within five days of symptom onset.</p><p><blockquote>为了最有效，需要在感染发生之前尽早给予抗病毒药物。默克公司在症状出现后五天内测试了其药物。</blockquote></p><p> \"We saw that we did have high efficacy, even if it was five days after a patient has been treated ... people might wait a couple of days before getting a test or something, and this means that we have time to treat people and really provide a benefit from a public health perspective,\" Annaliesa Anderson, head of the Pfizer program, told Reuters.</p><p><blockquote>“我们发现我们确实具有很高的疗效，即使是在患者接受治疗五天后……人们可能会等待几天才能进行测试或其他事情，这意味着我们有时间治疗人们并从公共卫生的角度来看确实提供了好处，”辉瑞项目负责人安娜莉莎·安德森告诉路透社。</blockquote></p><p> The company did not detail side effects of the treatment, but said adverse events happened in about 20% of both treatment and placebo patients.</p><p><blockquote>该公司没有详细说明治疗的副作用，但表示约20%的治疗和安慰剂患者发生了不良事件。</blockquote></p><p> \"These data suggest that our oral antiviral candidate, if approved by regulatory authorities, has the potential to save patients’ lives, reduce the severity of COVID-19 infections, and eliminate up to nine out of ten hospitalizations,” Pfizer Chief Executive Albert Bourla said in a statement.</p><p><blockquote>辉瑞首席执行官Albert Bourla表示：“这些数据表明，我们的口服抗病毒候选药物如果获得监管机构的批准，有可能挽救患者的生命，降低COVID-19感染的严重程度，并消除多达十分之九的住院治疗。”在一份声明中说。</blockquote></p><p> Infectious disease experts stress that preventing COVID-19 through wide use of vaccines remains the best way to control the pandemic, but only 58% of Americans are fully vaccinated and access in many parts of the world is limited.</p><p><blockquote>传染病专家强调，通过广泛使用疫苗来预防新冠肺炎仍然是控制疫情的最佳方式，但只有58%的美国人完全接种了疫苗，世界许多地区的疫苗接种有限。</blockquote></p><p> Pfizer's drug, part of a class known as protease inhibitors, is designed to block an enzyme the coronavirus needs in order to multiply.</p><p><blockquote>辉瑞的药物是蛋白酶抑制剂类药物的一部分，旨在阻断冠状病毒繁殖所需的酶。</blockquote></p><p> Merck's molnupiravir has a different mechanism of action designed to introduce errors into the genetic code of the virus. Merck has already sold millions of courses of the treatment, which was approved this week by U.K. regulators, to the United States, the U.K. and others.</p><p><blockquote>默克公司的molnupiravir具有不同的作用机制，旨在将错误引入病毒的遗传密码。默克公司已向美国、英国和其他国家出售了数百万个疗程的治疗药物，该药物本周获得了英国监管机构的批准。</blockquote></p><p> Britain said earlier this month it had secured 250,000 courses of Pfizer's antiviral.</p><p><blockquote>英国本月早些时候表示，已获得25万个疗程的辉瑞抗病毒药物。</blockquote></p><p> Pfizer is also studying whether its pill could be used by people without risk factors for serious COVID-19 as well as to prevent coronavirus infection in people exposed to the virus.</p><p><blockquote>辉瑞还在研究其药物是否可以被没有严重新冠肺炎风险因素的人使用，以及预防接触该病毒的人感染冠状病毒。</blockquote></p><p> Its&nbsp;shares&nbsp;rose&nbsp;over&nbsp;9%&nbsp;in&nbsp;premarket&nbsp;trading.<img src=\"https://static.tigerbbs.com/190a24394aa60d689cf29552569f5e20\" tg-width=\"774\" tg-height=\"567\" width=\"100%\" height=\"auto\"></p><p><blockquote>其股价在盘前交易中上涨超过9%。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1168526565","content_text":"A trial of Pfizer Inc's experimental antiviral pill for COVID-19 was stopped early after the drug was shown to cut by 89% the chances of hospitalization or death for adults at risk of developing severe disease, the company said on Friday.\nThe results appear to surpass those seen with Merck & Co Inc's pill molnupiravir, which was shown last month to halve the likelihood of dying or being hospitalized for COVID-19 patients also at high risk of serious illness.\nFull trial data is not yet available from either company.\nPfizer said it plans to submit interim trial results for its pill, which is given in combination with an older antiviral called ritonavir, to the U.S. Food and Drug Administration as part of the emergency use application it opened in October.\nThe combination treatment, which will have the brand name Paxlovid, consists of three pills given twice daily.\nThe planned analysis of 1,219 patients in Pfizer's study looked at hospitalizations or deaths among people diagnosed with mild to moderate COVID-19 with at least one risk factor for developing severe disease, such as obesity or older age.\nIt found that 0.8% of those given Pfizer's drug within three days of symptom onset were hospitalized and none had died by 28 days after treatment. That compared with a hospitalization rate of 7% for placebo patients. There were also seven deaths in the placebo group.\nRates were similar for patients treated within five days of symptoms - 1% of the treatment group was hospitalized, compared with 6.7% for the placebo group, which included 10 deaths.\nAntivirals need to be given as early as possible, before an infection takes hold, in order to be most effective. Merck tested its drug within five days of symptom onset.\n\"We saw that we did have high efficacy, even if it was five days after a patient has been treated ... people might wait a couple of days before getting a test or something, and this means that we have time to treat people and really provide a benefit from a public health perspective,\" Annaliesa Anderson, head of the Pfizer program, told Reuters.\nThe company did not detail side effects of the treatment, but said adverse events happened in about 20% of both treatment and placebo patients.\n\"These data suggest that our oral antiviral candidate, if approved by regulatory authorities, has the potential to save patients’ lives, reduce the severity of COVID-19 infections, and eliminate up to nine out of ten hospitalizations,” Pfizer Chief Executive Albert Bourla said in a statement.\nInfectious disease experts stress that preventing COVID-19 through wide use of vaccines remains the best way to control the pandemic, but only 58% of Americans are fully vaccinated and access in many parts of the world is limited.\nPfizer's drug, part of a class known as protease inhibitors, is designed to block an enzyme the coronavirus needs in order to multiply.\nMerck's molnupiravir has a different mechanism of action designed to introduce errors into the genetic code of the virus. Merck has already sold millions of courses of the treatment, which was approved this week by U.K. regulators, to the United States, the U.K. and others.\nBritain said earlier this month it had secured 250,000 courses of Pfizer's antiviral.\nPfizer is also studying whether its pill could be used by people without risk factors for serious COVID-19 as well as to prevent coronavirus infection in people exposed to the virus.\nIts shares rose over 9% in premarket trading.","news_type":1,"symbols_score_info":{"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":2681,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":846798097,"gmtCreate":1636111622666,"gmtModify":1636111622737,"author":{"id":"3574940915326235","authorId":"3574940915326235","name":"TheMysTrader","avatar":"https://static.tigerbbs.com/08abc512620038ac153ab0bf62705216","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574940915326235","idStr":"3574940915326235"},"themes":[],"htmlText":"Omg that's good news!&nbsp;","listText":"Omg that's good news!&nbsp;","text":"Omg that's good news!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/846798097","repostId":"1168526565","repostType":2,"repost":{"id":"1168526565","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1636109309,"share":"https://www.laohu8.com/m/news/1168526565?lang=zh_CN&edition=full","pubTime":"2021-11-05 18:48","market":"us","language":"en","title":"Pfizer rose over 9% in premarket trading as its antiviral pill cut risk of severe COVID-19 by 89%<blockquote>辉瑞(Pfizer)在盘前交易中上涨超过9%，其抗病毒药物将严重COVID-19的风险降低了89%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1168526565","media":"Tiger Newspress","summary":"A trial of Pfizer Inc's experimental antiviral pill for COVID-19 was stopped early after the drug wa","content":"<p>A trial of Pfizer Inc's experimental antiviral pill for COVID-19 was stopped early after the drug was shown to cut by 89% the chances of hospitalization or death for adults at risk of developing severe disease, the company said on Friday.</p><p><blockquote>辉瑞公司周五表示，该公司针对COVID-19的实验性抗病毒药物的试验提前停止，此前该药物被证明可以将有严重疾病风险的成年人住院或死亡的几率降低89%。</blockquote></p><p> The results appear to surpass those seen with Merck &amp; Co Inc's pill molnupiravir, which was shown last month to halve the likelihood of dying or being hospitalized for COVID-19 patients also at high risk of serious illness.</p><p><blockquote>这一结果似乎超过了默克公司(Merck&amp;Co Inc.)的药物molnupiravir的结果，该药物上个月被证明可以将同样具有严重疾病高风险的COVID-19患者死亡或住院的可能性减半。</blockquote></p><p> Full trial data is not yet available from either company.</p><p><blockquote>两家公司都尚未提供完整的试验数据。</blockquote></p><p> Pfizer said it plans to submit interim trial results for its pill, which is given in combination with an older antiviral called ritonavir, to the U.S. Food and Drug Administration as part of the emergency use application it opened in October.</p><p><blockquote>辉瑞表示，计划向美国提交其药物的中期试验结果，该药物与一种名为利托那韦的旧抗病毒药物联合使用。食品和药物管理局作为其10月份开放的紧急使用申请的一部分。</blockquote></p><p> The combination treatment, which will have the brand name Paxlovid, consists of three pills given twice daily.</p><p><blockquote>这种联合治疗的品牌名称为Paxlovid，包括每天两次服用三粒药丸。</blockquote></p><p> The planned analysis of 1,219 patients in Pfizer's study looked at hospitalizations or deaths among people diagnosed with mild to moderate COVID-19 with at least one risk factor for developing severe disease, such as obesity or older age.</p><p><blockquote>辉瑞研究中计划对1,219名患者进行分析，研究了被诊断患有轻度至中度COVID-19且至少有一种发展为严重疾病的风险因素（如肥胖或年龄较大）的人的住院或死亡情况。</blockquote></p><p> It found that 0.8% of those given Pfizer's drug within three days of symptom onset were hospitalized and none had died by 28 days after treatment. That compared with a hospitalization rate of 7% for placebo patients. There were also seven deaths in the placebo group.</p><p><blockquote>研究发现，在症状出现后三天内服用辉瑞药物的患者中，有0.8%住院治疗，没有人在治疗后28天内死亡。相比之下，安慰剂患者的住院率为7%。安慰剂组也有7例死亡。</blockquote></p><p> Rates were similar for patients treated within five days of symptoms - 1% of the treatment group was hospitalized, compared with 6.7% for the placebo group, which included 10 deaths.</p><p><blockquote>在出现症状5天内接受治疗的患者的比率相似——治疗组1%住院，而安慰剂组为6.7%，其中包括10例死亡。</blockquote></p><p> Antivirals need to be given as early as possible, before an infection takes hold, in order to be most effective. Merck tested its drug within five days of symptom onset.</p><p><blockquote>为了最有效，需要在感染发生之前尽早给予抗病毒药物。默克公司在症状出现后五天内测试了其药物。</blockquote></p><p> \"We saw that we did have high efficacy, even if it was five days after a patient has been treated ... people might wait a couple of days before getting a test or something, and this means that we have time to treat people and really provide a benefit from a public health perspective,\" Annaliesa Anderson, head of the Pfizer program, told Reuters.</p><p><blockquote>“我们发现我们确实具有很高的疗效，即使是在患者接受治疗五天后……人们可能会等待几天才能进行测试或其他事情，这意味着我们有时间治疗人们并从公共卫生的角度来看确实提供了好处，”辉瑞项目负责人安娜莉莎·安德森告诉路透社。</blockquote></p><p> The company did not detail side effects of the treatment, but said adverse events happened in about 20% of both treatment and placebo patients.</p><p><blockquote>该公司没有详细说明治疗的副作用，但表示约20%的治疗和安慰剂患者发生了不良事件。</blockquote></p><p> \"These data suggest that our oral antiviral candidate, if approved by regulatory authorities, has the potential to save patients’ lives, reduce the severity of COVID-19 infections, and eliminate up to nine out of ten hospitalizations,” Pfizer Chief Executive Albert Bourla said in a statement.</p><p><blockquote>辉瑞首席执行官Albert Bourla表示：“这些数据表明，我们的口服抗病毒候选药物如果获得监管机构的批准，有可能挽救患者的生命，降低COVID-19感染的严重程度，并消除多达十分之九的住院治疗。”在一份声明中说。</blockquote></p><p> Infectious disease experts stress that preventing COVID-19 through wide use of vaccines remains the best way to control the pandemic, but only 58% of Americans are fully vaccinated and access in many parts of the world is limited.</p><p><blockquote>传染病专家强调，通过广泛使用疫苗来预防新冠肺炎仍然是控制疫情的最佳方式，但只有58%的美国人完全接种了疫苗，世界许多地区的疫苗接种有限。</blockquote></p><p> Pfizer's drug, part of a class known as protease inhibitors, is designed to block an enzyme the coronavirus needs in order to multiply.</p><p><blockquote>辉瑞的药物是蛋白酶抑制剂类药物的一部分，旨在阻断冠状病毒繁殖所需的酶。</blockquote></p><p> Merck's molnupiravir has a different mechanism of action designed to introduce errors into the genetic code of the virus. Merck has already sold millions of courses of the treatment, which was approved this week by U.K. regulators, to the United States, the U.K. and others.</p><p><blockquote>默克公司的molnupiravir具有不同的作用机制，旨在将错误引入病毒的遗传密码。默克公司已向美国、英国和其他国家出售了数百万个疗程的治疗药物，该药物本周获得了英国监管机构的批准。</blockquote></p><p> Britain said earlier this month it had secured 250,000 courses of Pfizer's antiviral.</p><p><blockquote>英国本月早些时候表示，已获得25万个疗程的辉瑞抗病毒药物。</blockquote></p><p> Pfizer is also studying whether its pill could be used by people without risk factors for serious COVID-19 as well as to prevent coronavirus infection in people exposed to the virus.</p><p><blockquote>辉瑞还在研究其药物是否可以被没有严重新冠肺炎风险因素的人使用，以及预防接触该病毒的人感染冠状病毒。</blockquote></p><p> Its&nbsp;shares&nbsp;rose&nbsp;over&nbsp;9%&nbsp;in&nbsp;premarket&nbsp;trading.<img src=\"https://static.tigerbbs.com/190a24394aa60d689cf29552569f5e20\" tg-width=\"774\" tg-height=\"567\" width=\"100%\" height=\"auto\"></p><p><blockquote>其股价在盘前交易中上涨超过9%。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer rose over 9% in premarket trading as its antiviral pill cut risk of severe COVID-19 by 89%<blockquote>辉瑞(Pfizer)在盘前交易中上涨超过9%，其抗病毒药物将严重COVID-19的风险降低了89%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer rose over 9% in premarket trading as its antiviral pill cut risk of severe COVID-19 by 89%<blockquote>辉瑞(Pfizer)在盘前交易中上涨超过9%，其抗病毒药物将严重COVID-19的风险降低了89%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-11-05 18:48</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>A trial of Pfizer Inc's experimental antiviral pill for COVID-19 was stopped early after the drug was shown to cut by 89% the chances of hospitalization or death for adults at risk of developing severe disease, the company said on Friday.</p><p><blockquote>辉瑞公司周五表示，该公司针对COVID-19的实验性抗病毒药物的试验提前停止，此前该药物被证明可以将有严重疾病风险的成年人住院或死亡的几率降低89%。</blockquote></p><p> The results appear to surpass those seen with Merck &amp; Co Inc's pill molnupiravir, which was shown last month to halve the likelihood of dying or being hospitalized for COVID-19 patients also at high risk of serious illness.</p><p><blockquote>这一结果似乎超过了默克公司(Merck&amp;Co Inc.)的药物molnupiravir的结果，该药物上个月被证明可以将同样具有严重疾病高风险的COVID-19患者死亡或住院的可能性减半。</blockquote></p><p> Full trial data is not yet available from either company.</p><p><blockquote>两家公司都尚未提供完整的试验数据。</blockquote></p><p> Pfizer said it plans to submit interim trial results for its pill, which is given in combination with an older antiviral called ritonavir, to the U.S. Food and Drug Administration as part of the emergency use application it opened in October.</p><p><blockquote>辉瑞表示，计划向美国提交其药物的中期试验结果，该药物与一种名为利托那韦的旧抗病毒药物联合使用。食品和药物管理局作为其10月份开放的紧急使用申请的一部分。</blockquote></p><p> The combination treatment, which will have the brand name Paxlovid, consists of three pills given twice daily.</p><p><blockquote>这种联合治疗的品牌名称为Paxlovid，包括每天两次服用三粒药丸。</blockquote></p><p> The planned analysis of 1,219 patients in Pfizer's study looked at hospitalizations or deaths among people diagnosed with mild to moderate COVID-19 with at least one risk factor for developing severe disease, such as obesity or older age.</p><p><blockquote>辉瑞研究中计划对1,219名患者进行分析，研究了被诊断患有轻度至中度COVID-19且至少有一种发展为严重疾病的风险因素（如肥胖或年龄较大）的人的住院或死亡情况。</blockquote></p><p> It found that 0.8% of those given Pfizer's drug within three days of symptom onset were hospitalized and none had died by 28 days after treatment. That compared with a hospitalization rate of 7% for placebo patients. There were also seven deaths in the placebo group.</p><p><blockquote>研究发现，在症状出现后三天内服用辉瑞药物的患者中，有0.8%住院治疗，没有人在治疗后28天内死亡。相比之下，安慰剂患者的住院率为7%。安慰剂组也有7例死亡。</blockquote></p><p> Rates were similar for patients treated within five days of symptoms - 1% of the treatment group was hospitalized, compared with 6.7% for the placebo group, which included 10 deaths.</p><p><blockquote>在出现症状5天内接受治疗的患者的比率相似——治疗组1%住院，而安慰剂组为6.7%，其中包括10例死亡。</blockquote></p><p> Antivirals need to be given as early as possible, before an infection takes hold, in order to be most effective. Merck tested its drug within five days of symptom onset.</p><p><blockquote>为了最有效，需要在感染发生之前尽早给予抗病毒药物。默克公司在症状出现后五天内测试了其药物。</blockquote></p><p> \"We saw that we did have high efficacy, even if it was five days after a patient has been treated ... people might wait a couple of days before getting a test or something, and this means that we have time to treat people and really provide a benefit from a public health perspective,\" Annaliesa Anderson, head of the Pfizer program, told Reuters.</p><p><blockquote>“我们发现我们确实具有很高的疗效，即使是在患者接受治疗五天后……人们可能会等待几天才能进行测试或其他事情，这意味着我们有时间治疗人们并从公共卫生的角度来看确实提供了好处，”辉瑞项目负责人安娜莉莎·安德森告诉路透社。</blockquote></p><p> The company did not detail side effects of the treatment, but said adverse events happened in about 20% of both treatment and placebo patients.</p><p><blockquote>该公司没有详细说明治疗的副作用，但表示约20%的治疗和安慰剂患者发生了不良事件。</blockquote></p><p> \"These data suggest that our oral antiviral candidate, if approved by regulatory authorities, has the potential to save patients’ lives, reduce the severity of COVID-19 infections, and eliminate up to nine out of ten hospitalizations,” Pfizer Chief Executive Albert Bourla said in a statement.</p><p><blockquote>辉瑞首席执行官Albert Bourla表示：“这些数据表明，我们的口服抗病毒候选药物如果获得监管机构的批准，有可能挽救患者的生命，降低COVID-19感染的严重程度，并消除多达十分之九的住院治疗。”在一份声明中说。</blockquote></p><p> Infectious disease experts stress that preventing COVID-19 through wide use of vaccines remains the best way to control the pandemic, but only 58% of Americans are fully vaccinated and access in many parts of the world is limited.</p><p><blockquote>传染病专家强调，通过广泛使用疫苗来预防新冠肺炎仍然是控制疫情的最佳方式，但只有58%的美国人完全接种了疫苗，世界许多地区的疫苗接种有限。</blockquote></p><p> Pfizer's drug, part of a class known as protease inhibitors, is designed to block an enzyme the coronavirus needs in order to multiply.</p><p><blockquote>辉瑞的药物是蛋白酶抑制剂类药物的一部分，旨在阻断冠状病毒繁殖所需的酶。</blockquote></p><p> Merck's molnupiravir has a different mechanism of action designed to introduce errors into the genetic code of the virus. Merck has already sold millions of courses of the treatment, which was approved this week by U.K. regulators, to the United States, the U.K. and others.</p><p><blockquote>默克公司的molnupiravir具有不同的作用机制，旨在将错误引入病毒的遗传密码。默克公司已向美国、英国和其他国家出售了数百万个疗程的治疗药物，该药物本周获得了英国监管机构的批准。</blockquote></p><p> Britain said earlier this month it had secured 250,000 courses of Pfizer's antiviral.</p><p><blockquote>英国本月早些时候表示，已获得25万个疗程的辉瑞抗病毒药物。</blockquote></p><p> Pfizer is also studying whether its pill could be used by people without risk factors for serious COVID-19 as well as to prevent coronavirus infection in people exposed to the virus.</p><p><blockquote>辉瑞还在研究其药物是否可以被没有严重新冠肺炎风险因素的人使用，以及预防接触该病毒的人感染冠状病毒。</blockquote></p><p> Its&nbsp;shares&nbsp;rose&nbsp;over&nbsp;9%&nbsp;in&nbsp;premarket&nbsp;trading.<img src=\"https://static.tigerbbs.com/190a24394aa60d689cf29552569f5e20\" tg-width=\"774\" tg-height=\"567\" width=\"100%\" height=\"auto\"></p><p><blockquote>其股价在盘前交易中上涨超过9%。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1168526565","content_text":"A trial of Pfizer Inc's experimental antiviral pill for COVID-19 was stopped early after the drug was shown to cut by 89% the chances of hospitalization or death for adults at risk of developing severe disease, the company said on Friday.\nThe results appear to surpass those seen with Merck & Co Inc's pill molnupiravir, which was shown last month to halve the likelihood of dying or being hospitalized for COVID-19 patients also at high risk of serious illness.\nFull trial data is not yet available from either company.\nPfizer said it plans to submit interim trial results for its pill, which is given in combination with an older antiviral called ritonavir, to the U.S. Food and Drug Administration as part of the emergency use application it opened in October.\nThe combination treatment, which will have the brand name Paxlovid, consists of three pills given twice daily.\nThe planned analysis of 1,219 patients in Pfizer's study looked at hospitalizations or deaths among people diagnosed with mild to moderate COVID-19 with at least one risk factor for developing severe disease, such as obesity or older age.\nIt found that 0.8% of those given Pfizer's drug within three days of symptom onset were hospitalized and none had died by 28 days after treatment. That compared with a hospitalization rate of 7% for placebo patients. There were also seven deaths in the placebo group.\nRates were similar for patients treated within five days of symptoms - 1% of the treatment group was hospitalized, compared with 6.7% for the placebo group, which included 10 deaths.\nAntivirals need to be given as early as possible, before an infection takes hold, in order to be most effective. Merck tested its drug within five days of symptom onset.\n\"We saw that we did have high efficacy, even if it was five days after a patient has been treated ... people might wait a couple of days before getting a test or something, and this means that we have time to treat people and really provide a benefit from a public health perspective,\" Annaliesa Anderson, head of the Pfizer program, told Reuters.\nThe company did not detail side effects of the treatment, but said adverse events happened in about 20% of both treatment and placebo patients.\n\"These data suggest that our oral antiviral candidate, if approved by regulatory authorities, has the potential to save patients’ lives, reduce the severity of COVID-19 infections, and eliminate up to nine out of ten hospitalizations,” Pfizer Chief Executive Albert Bourla said in a statement.\nInfectious disease experts stress that preventing COVID-19 through wide use of vaccines remains the best way to control the pandemic, but only 58% of Americans are fully vaccinated and access in many parts of the world is limited.\nPfizer's drug, part of a class known as protease inhibitors, is designed to block an enzyme the coronavirus needs in order to multiply.\nMerck's molnupiravir has a different mechanism of action designed to introduce errors into the genetic code of the virus. Merck has already sold millions of courses of the treatment, which was approved this week by U.K. regulators, to the United States, the U.K. and others.\nBritain said earlier this month it had secured 250,000 courses of Pfizer's antiviral.\nPfizer is also studying whether its pill could be used by people without risk factors for serious COVID-19 as well as to prevent coronavirus infection in people exposed to the virus.\nIts shares rose over 9% in premarket trading.","news_type":1,"symbols_score_info":{"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":2625,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":853937233,"gmtCreate":1634755270098,"gmtModify":1634755270227,"author":{"id":"3574940915326235","authorId":"3574940915326235","name":"TheMysTrader","avatar":"https://static.tigerbbs.com/08abc512620038ac153ab0bf62705216","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574940915326235","idStr":"3574940915326235"},"themes":[],"htmlText":"Will&nbsp;<a href=\"https://laohu8.com/S/TSLA\">$Tesla Motors(TSLA)$</a>hit 900 alike earlier part of the year?&nbsp;","listText":"Will&nbsp;<a href=\"https://laohu8.com/S/TSLA\">$Tesla Motors(TSLA)$</a>hit 900 alike earlier part of the year?&nbsp;","text":"Will $Tesla Motors(TSLA)$hit 900 alike earlier part of the year?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/853937233","isVote":1,"tweetType":1,"viewCount":1927,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":128865013,"gmtCreate":1624510533832,"gmtModify":1634005038213,"author":{"id":"3574940915326235","authorId":"3574940915326235","name":"TheMysTrader","avatar":"https://static.tigerbbs.com/08abc512620038ac153ab0bf62705216","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574940915326235","idStr":"3574940915326235"},"themes":[],"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/128865013","repostId":"1170004118","repostType":4,"isVote":1,"tweetType":1,"viewCount":1341,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":128868955,"gmtCreate":1624510444177,"gmtModify":1634005040737,"author":{"id":"3574940915326235","authorId":"3574940915326235","name":"TheMysTrader","avatar":"https://static.tigerbbs.com/08abc512620038ac153ab0bf62705216","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574940915326235","idStr":"3574940915326235"},"themes":[],"htmlText":"Bbtea ❤️","listText":"Bbtea ❤️","text":"Bbtea ❤️","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/128868955","repostId":"1178700711","repostType":4,"repost":{"id":"1178700711","kind":"news","pubTimestamp":1624497882,"share":"https://www.laohu8.com/m/news/1178700711?lang=zh_CN&edition=full","pubTime":"2021-06-24 09:24","market":"hk","language":"en","title":"Bubble Tea Chain Raises $656 Million in Hong Kong IPO<blockquote>珍珠奶茶连锁店香港IPO融资6.56亿美元</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1178700711","media":"Bloomberg","summary":"(Bloomberg) -- Chinese bubble tea chain Nayuki Holdings Ltd. has raised HK$5.09 billion ($656 millio","content":"<p>(Bloomberg) -- Chinese bubble tea chain Nayuki Holdings Ltd. has raised HK$5.09 billion ($656 million) after pricing its Hong Kong initial public offering at the top of a marketed range, the latest company to ride a resurgence of listings in the Asian financial hub.</p><p><blockquote>（彭博社）-中国珍珠奶茶连锁店奈雪控股有限公司在香港首次公开募股定价高于市场范围后，筹集了50.9亿港元（6.56亿美元），这是最新一家在亚洲金融中心上市复苏的公司。</blockquote></p><p> Nayuki, whose popular fresh-fruit teas include cheese-foam-topped beverages, has priced 257.3 million shares at HK$19.8 each, according to terms of the deal obtained by Bloomberg News. It had marketed the shares at HK$17.2 to HK$19.8 apiece.</p><p><blockquote>根据彭博新闻社获得的交易条款，奈雪的受欢迎的鲜果茶包括芝士泡沫饮料，该公司以每股19.8港元的价格发行了2.573亿股股票。该公司以每股17.2港元至19.8港元的价格出售股份。</blockquote></p><p> The teahouse operator is testing the waters after Angelalign Technology Inc., a maker of clear orthodontic braces, heralded a revival in Hong Kong’s IPO market with a massive 132% pop on its June 16 debut, becoming one of this year’s most popular offerings in the city.</p><p><blockquote>透明正畸牙套制造商时代天使科技公司(Angelalign Technology Inc.)在6月16日首次亮相时股价飙升132%，成为今年香港最受欢迎的产品之一，预示着香港IPO市场的复苏，这家茶馆运营商正在试水。</blockquote></p><p> First-time share sales in Hong Kong are ticking up after a period of muted activity, as an easing of the global tech selloff has created a more favorable backdrop for debuts. At least 13 companies are currently in the lineup to go public, compared to only two deals priced in April and four in May, according to data compiled by Bloomberg.</p><p><blockquote>在经历了一段时间的低迷活动后，香港的首次公开募股销售正在回升，因为全球科技股抛售的缓解为首次公开募股创造了更有利的背景。根据彭博社汇编的数据，目前至少有13家公司正在准备上市，而4月份只有两笔交易定价，5月份有四笔交易定价。</blockquote></p><p> Still, not every IPO is getting a warm welcome as investors have become more selective amid higher volatility in markets and growing expectations of a tightening of U.S. monetary policy. China Youran Dairy Group Ltd. and CARsgen Therapeutics Holdings Ltd. slumped 12% and 9%, respectively, in their trading debuts last Friday.</p><p><blockquote>尽管如此，并非每一次IPO都受到热烈欢迎，因为在市场波动加剧和对美国货币政策收紧的预期不断增强的情况下，投资者变得更加挑剔。中国优然乳业集团有限公司和科济药业控股有限公司上周五首次上市时分别下跌12%和9%。</blockquote></p><p> Nayuki’s share sale attracted five cornerstone investors who agreed to subscribe for about $155 million of stock. They are UBS Asset Management, China Universal Asset Management, GF Fund, China Southern Asset Management and CCB International, according to the prospectus.</p><p><blockquote>奈雪的股票出售吸引了五名基石投资者，他们同意认购约1.55亿美元的股票。根据招股说明书，它们是瑞银资产管理、汇添富资产管理、广发基金、南方基金和建银国际。</blockquote></p><p> The retail portion of Nayuki’s IPO was more than 400 times oversubscribed, the Hong Kong Economic Journal reported, citing people it didn’t identify.</p><p><blockquote>据《信报》援引未透露姓名的人士报道，奈雪的IPO零售部分超额认购超过400倍。</blockquote></p><p> The top-of-the-range pricing values the bubble tea chain at about $4.38 billion, up from the $2 billion in its last funding round. It originally planned to file for an IPO in the U.S. in February last year, Bloomberg News reported, but eventually opted for Hong Kong.</p><p><blockquote>顶级定价对这家珍珠奶茶连锁店的估值约为43.8亿美元，高于上一轮融资的20亿美元。据彭博社报道，该公司最初计划于去年2月在美国申请IPO，但最终选择了香港。</blockquote></p><p> The Shenzhen-based firm sells fresh-fruit teas, cold-brew beverages and baked goods. It recorded losses of 203 million yuan in 2020 and 40 million yuan in the previous year, according to its prospectus. Revenue rose 22% year-on-year to 3.1 billion yuan.</p><p><blockquote>这家总部位于深圳的公司销售鲜果茶、冷饮和烘焙食品。招股书显示，该公司2020年亏损2.03亿元，上年亏损4000万元。营收同比升22%至31亿元。</blockquote></p><p> Nayuki plans to use proceeds from the offering to expand its teahouse network, deepen market penetration and strengthen its supply chain. It had 491 flagship Nayuki outlets at the end of last year, including 489 in mainland China and one each in Hong Kong and Japan.</p><p><blockquote>奈雪计划将此次发行所得用于扩大其茶馆网络、深化市场渗透并加强其供应链。截至去年底，其拥有491家奈雪旗舰店，其中中国内地489家，香港和日本各1家。</blockquote></p><p> Nayuki’s shares are set to start trading in Hong Kong on June 30. JPMorgan Chase &amp; Co., CMB International Capital Ltd. and Huatai International Ltd. are joint sponsors for the listing.</p><p><blockquote>奈雪的股票定于6月30日在香港开始交易。摩根大通、招银国际金融有限公司及华泰国际有限公司为本次上市的联席保荐人。</blockquote></p><p></p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bubble Tea Chain Raises $656 Million in Hong Kong IPO<blockquote>珍珠奶茶连锁店香港IPO融资6.56亿美元</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBubble Tea Chain Raises $656 Million in Hong Kong IPO<blockquote>珍珠奶茶连锁店香港IPO融资6.56亿美元</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Bloomberg</strong><span class=\"h-time small\">2021-06-24 09:24</span>\n</p>\n</h4>\n</header>\n<article>\n<p>(Bloomberg) -- Chinese bubble tea chain Nayuki Holdings Ltd. has raised HK$5.09 billion ($656 million) after pricing its Hong Kong initial public offering at the top of a marketed range, the latest company to ride a resurgence of listings in the Asian financial hub.</p><p><blockquote>（彭博社）-中国珍珠奶茶连锁店奈雪控股有限公司在香港首次公开募股定价高于市场范围后，筹集了50.9亿港元（6.56亿美元），这是最新一家在亚洲金融中心上市复苏的公司。</blockquote></p><p> Nayuki, whose popular fresh-fruit teas include cheese-foam-topped beverages, has priced 257.3 million shares at HK$19.8 each, according to terms of the deal obtained by Bloomberg News. It had marketed the shares at HK$17.2 to HK$19.8 apiece.</p><p><blockquote>根据彭博新闻社获得的交易条款，奈雪的受欢迎的鲜果茶包括芝士泡沫饮料，该公司以每股19.8港元的价格发行了2.573亿股股票。该公司以每股17.2港元至19.8港元的价格出售股份。</blockquote></p><p> The teahouse operator is testing the waters after Angelalign Technology Inc., a maker of clear orthodontic braces, heralded a revival in Hong Kong’s IPO market with a massive 132% pop on its June 16 debut, becoming one of this year’s most popular offerings in the city.</p><p><blockquote>透明正畸牙套制造商时代天使科技公司(Angelalign Technology Inc.)在6月16日首次亮相时股价飙升132%，成为今年香港最受欢迎的产品之一，预示着香港IPO市场的复苏，这家茶馆运营商正在试水。</blockquote></p><p> First-time share sales in Hong Kong are ticking up after a period of muted activity, as an easing of the global tech selloff has created a more favorable backdrop for debuts. At least 13 companies are currently in the lineup to go public, compared to only two deals priced in April and four in May, according to data compiled by Bloomberg.</p><p><blockquote>在经历了一段时间的低迷活动后，香港的首次公开募股销售正在回升，因为全球科技股抛售的缓解为首次公开募股创造了更有利的背景。根据彭博社汇编的数据，目前至少有13家公司正在准备上市，而4月份只有两笔交易定价，5月份有四笔交易定价。</blockquote></p><p> Still, not every IPO is getting a warm welcome as investors have become more selective amid higher volatility in markets and growing expectations of a tightening of U.S. monetary policy. China Youran Dairy Group Ltd. and CARsgen Therapeutics Holdings Ltd. slumped 12% and 9%, respectively, in their trading debuts last Friday.</p><p><blockquote>尽管如此，并非每一次IPO都受到热烈欢迎，因为在市场波动加剧和对美国货币政策收紧的预期不断增强的情况下，投资者变得更加挑剔。中国优然乳业集团有限公司和科济药业控股有限公司上周五首次上市时分别下跌12%和9%。</blockquote></p><p> Nayuki’s share sale attracted five cornerstone investors who agreed to subscribe for about $155 million of stock. They are UBS Asset Management, China Universal Asset Management, GF Fund, China Southern Asset Management and CCB International, according to the prospectus.</p><p><blockquote>奈雪的股票出售吸引了五名基石投资者，他们同意认购约1.55亿美元的股票。根据招股说明书，它们是瑞银资产管理、汇添富资产管理、广发基金、南方基金和建银国际。</blockquote></p><p> The retail portion of Nayuki’s IPO was more than 400 times oversubscribed, the Hong Kong Economic Journal reported, citing people it didn’t identify.</p><p><blockquote>据《信报》援引未透露姓名的人士报道，奈雪的IPO零售部分超额认购超过400倍。</blockquote></p><p> The top-of-the-range pricing values the bubble tea chain at about $4.38 billion, up from the $2 billion in its last funding round. It originally planned to file for an IPO in the U.S. in February last year, Bloomberg News reported, but eventually opted for Hong Kong.</p><p><blockquote>顶级定价对这家珍珠奶茶连锁店的估值约为43.8亿美元，高于上一轮融资的20亿美元。据彭博社报道，该公司最初计划于去年2月在美国申请IPO，但最终选择了香港。</blockquote></p><p> The Shenzhen-based firm sells fresh-fruit teas, cold-brew beverages and baked goods. It recorded losses of 203 million yuan in 2020 and 40 million yuan in the previous year, according to its prospectus. Revenue rose 22% year-on-year to 3.1 billion yuan.</p><p><blockquote>这家总部位于深圳的公司销售鲜果茶、冷饮和烘焙食品。招股书显示，该公司2020年亏损2.03亿元，上年亏损4000万元。营收同比升22%至31亿元。</blockquote></p><p> Nayuki plans to use proceeds from the offering to expand its teahouse network, deepen market penetration and strengthen its supply chain. It had 491 flagship Nayuki outlets at the end of last year, including 489 in mainland China and one each in Hong Kong and Japan.</p><p><blockquote>奈雪计划将此次发行所得用于扩大其茶馆网络、深化市场渗透并加强其供应链。截至去年底，其拥有491家奈雪旗舰店，其中中国内地489家，香港和日本各1家。</blockquote></p><p> Nayuki’s shares are set to start trading in Hong Kong on June 30. JPMorgan Chase &amp; Co., CMB International Capital Ltd. and Huatai International Ltd. are joint sponsors for the listing.</p><p><blockquote>奈雪的股票定于6月30日在香港开始交易。摩根大通、招银国际金融有限公司及华泰国际有限公司为本次上市的联席保荐人。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://finance.yahoo.com/news/bubble-tea-chain-said-raise-111206490.html\">Bloomberg</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"02150":"奈雪的茶"},"source_url":"https://finance.yahoo.com/news/bubble-tea-chain-said-raise-111206490.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1178700711","content_text":"(Bloomberg) -- Chinese bubble tea chain Nayuki Holdings Ltd. has raised HK$5.09 billion ($656 million) after pricing its Hong Kong initial public offering at the top of a marketed range, the latest company to ride a resurgence of listings in the Asian financial hub.\nNayuki, whose popular fresh-fruit teas include cheese-foam-topped beverages, has priced 257.3 million shares at HK$19.8 each, according to terms of the deal obtained by Bloomberg News. It had marketed the shares at HK$17.2 to HK$19.8 apiece.\nThe teahouse operator is testing the waters after Angelalign Technology Inc., a maker of clear orthodontic braces, heralded a revival in Hong Kong’s IPO market with a massive 132% pop on its June 16 debut, becoming one of this year’s most popular offerings in the city.\nFirst-time share sales in Hong Kong are ticking up after a period of muted activity, as an easing of the global tech selloff has created a more favorable backdrop for debuts. At least 13 companies are currently in the lineup to go public, compared to only two deals priced in April and four in May, according to data compiled by Bloomberg.\nStill, not every IPO is getting a warm welcome as investors have become more selective amid higher volatility in markets and growing expectations of a tightening of U.S. monetary policy. China Youran Dairy Group Ltd. and CARsgen Therapeutics Holdings Ltd. slumped 12% and 9%, respectively, in their trading debuts last Friday.\nNayuki’s share sale attracted five cornerstone investors who agreed to subscribe for about $155 million of stock. They are UBS Asset Management, China Universal Asset Management, GF Fund, China Southern Asset Management and CCB International, according to the prospectus.\nThe retail portion of Nayuki’s IPO was more than 400 times oversubscribed, the Hong Kong Economic Journal reported, citing people it didn’t identify.\nThe top-of-the-range pricing values the bubble tea chain at about $4.38 billion, up from the $2 billion in its last funding round. It originally planned to file for an IPO in the U.S. in February last year, Bloomberg News reported, but eventually opted for Hong Kong.\nThe Shenzhen-based firm sells fresh-fruit teas, cold-brew beverages and baked goods. It recorded losses of 203 million yuan in 2020 and 40 million yuan in the previous year, according to its prospectus. Revenue rose 22% year-on-year to 3.1 billion yuan.\nNayuki plans to use proceeds from the offering to expand its teahouse network, deepen market penetration and strengthen its supply chain. It had 491 flagship Nayuki outlets at the end of last year, including 489 in mainland China and one each in Hong Kong and Japan.\nNayuki’s shares are set to start trading in Hong Kong on June 30. JPMorgan Chase & Co., CMB International Capital Ltd. and Huatai International Ltd. are joint sponsors for the listing.","news_type":1,"symbols_score_info":{"02150":0.9}},"isVote":1,"tweetType":1,"viewCount":1400,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":163327019,"gmtCreate":1623860210331,"gmtModify":1634026865490,"author":{"id":"3574940915326235","authorId":"3574940915326235","name":"TheMysTrader","avatar":"https://static.tigerbbs.com/08abc512620038ac153ab0bf62705216","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574940915326235","idStr":"3574940915326235"},"themes":[],"htmlText":"Wow[得意]&nbsp;","listText":"Wow[得意]&nbsp;","text":"Wow[得意]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/163327019","repostId":"2143978737","repostType":4,"isVote":1,"tweetType":1,"viewCount":1964,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":163328074,"gmtCreate":1623860099598,"gmtModify":1634026869600,"author":{"id":"3574940915326235","authorId":"3574940915326235","name":"TheMysTrader","avatar":"https://static.tigerbbs.com/08abc512620038ac153ab0bf62705216","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574940915326235","idStr":"3574940915326235"},"themes":[],"htmlText":"Interesting","listText":"Interesting","text":"Interesting","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/163328074","repostId":"2143978737","repostType":4,"isVote":1,"tweetType":1,"viewCount":1401,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":846797989,"gmtCreate":1636112138356,"gmtModify":1636112280599,"author":{"id":"3574940915326235","authorId":"3574940915326235","name":"TheMysTrader","avatar":"https://static.tigerbbs.com/08abc512620038ac153ab0bf62705216","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574940915326235","idStr":"3574940915326235"},"themes":[],"htmlText":"Will Pfizer for once pfi(fly) up to the moon?&nbsp;[财迷]&nbsp;","listText":"Will Pfizer for once pfi(fly) up to the moon?&nbsp;[财迷]&nbsp;","text":"Will Pfizer for once pfi(fly) up to the moon? [财迷]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/846797989","repostId":"1168526565","repostType":2,"repost":{"id":"1168526565","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1636109309,"share":"https://www.laohu8.com/m/news/1168526565?lang=zh_CN&edition=full","pubTime":"2021-11-05 18:48","market":"us","language":"en","title":"Pfizer rose over 9% in premarket trading as its antiviral pill cut risk of severe COVID-19 by 89%<blockquote>辉瑞(Pfizer)在盘前交易中上涨超过9%，其抗病毒药物将严重COVID-19的风险降低了89%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1168526565","media":"Tiger Newspress","summary":"A trial of Pfizer Inc's experimental antiviral pill for COVID-19 was stopped early after the drug wa","content":"<p>A trial of Pfizer Inc's experimental antiviral pill for COVID-19 was stopped early after the drug was shown to cut by 89% the chances of hospitalization or death for adults at risk of developing severe disease, the company said on Friday.</p><p><blockquote>辉瑞公司周五表示，该公司针对COVID-19的实验性抗病毒药物的试验提前停止，此前该药物被证明可以将有严重疾病风险的成年人住院或死亡的几率降低89%。</blockquote></p><p> The results appear to surpass those seen with Merck &amp; Co Inc's pill molnupiravir, which was shown last month to halve the likelihood of dying or being hospitalized for COVID-19 patients also at high risk of serious illness.</p><p><blockquote>这一结果似乎超过了默克公司(Merck&amp;Co Inc.)的药物molnupiravir的结果，该药物上个月被证明可以将同样具有严重疾病高风险的COVID-19患者死亡或住院的可能性减半。</blockquote></p><p> Full trial data is not yet available from either company.</p><p><blockquote>两家公司都尚未提供完整的试验数据。</blockquote></p><p> Pfizer said it plans to submit interim trial results for its pill, which is given in combination with an older antiviral called ritonavir, to the U.S. Food and Drug Administration as part of the emergency use application it opened in October.</p><p><blockquote>辉瑞表示，计划向美国提交其药物的中期试验结果，该药物与一种名为利托那韦的旧抗病毒药物联合使用。食品和药物管理局作为其10月份开放的紧急使用申请的一部分。</blockquote></p><p> The combination treatment, which will have the brand name Paxlovid, consists of three pills given twice daily.</p><p><blockquote>这种联合治疗的品牌名称为Paxlovid，包括每天两次服用三粒药丸。</blockquote></p><p> The planned analysis of 1,219 patients in Pfizer's study looked at hospitalizations or deaths among people diagnosed with mild to moderate COVID-19 with at least one risk factor for developing severe disease, such as obesity or older age.</p><p><blockquote>辉瑞研究中计划对1,219名患者进行分析，研究了被诊断患有轻度至中度COVID-19且至少有一种发展为严重疾病的风险因素（如肥胖或年龄较大）的人的住院或死亡情况。</blockquote></p><p> It found that 0.8% of those given Pfizer's drug within three days of symptom onset were hospitalized and none had died by 28 days after treatment. That compared with a hospitalization rate of 7% for placebo patients. There were also seven deaths in the placebo group.</p><p><blockquote>研究发现，在症状出现后三天内服用辉瑞药物的患者中，有0.8%住院治疗，没有人在治疗后28天内死亡。相比之下，安慰剂患者的住院率为7%。安慰剂组也有7例死亡。</blockquote></p><p> Rates were similar for patients treated within five days of symptoms - 1% of the treatment group was hospitalized, compared with 6.7% for the placebo group, which included 10 deaths.</p><p><blockquote>在出现症状5天内接受治疗的患者的比率相似——治疗组1%住院，而安慰剂组为6.7%，其中包括10例死亡。</blockquote></p><p> Antivirals need to be given as early as possible, before an infection takes hold, in order to be most effective. Merck tested its drug within five days of symptom onset.</p><p><blockquote>为了最有效，需要在感染发生之前尽早给予抗病毒药物。默克公司在症状出现后五天内测试了其药物。</blockquote></p><p> \"We saw that we did have high efficacy, even if it was five days after a patient has been treated ... people might wait a couple of days before getting a test or something, and this means that we have time to treat people and really provide a benefit from a public health perspective,\" Annaliesa Anderson, head of the Pfizer program, told Reuters.</p><p><blockquote>“我们发现我们确实具有很高的疗效，即使是在患者接受治疗五天后……人们可能会等待几天才能进行测试或其他事情，这意味着我们有时间治疗人们并从公共卫生的角度来看确实提供了好处，”辉瑞项目负责人安娜莉莎·安德森告诉路透社。</blockquote></p><p> The company did not detail side effects of the treatment, but said adverse events happened in about 20% of both treatment and placebo patients.</p><p><blockquote>该公司没有详细说明治疗的副作用，但表示约20%的治疗和安慰剂患者发生了不良事件。</blockquote></p><p> \"These data suggest that our oral antiviral candidate, if approved by regulatory authorities, has the potential to save patients’ lives, reduce the severity of COVID-19 infections, and eliminate up to nine out of ten hospitalizations,” Pfizer Chief Executive Albert Bourla said in a statement.</p><p><blockquote>辉瑞首席执行官Albert Bourla表示：“这些数据表明，我们的口服抗病毒候选药物如果获得监管机构的批准，有可能挽救患者的生命，降低COVID-19感染的严重程度，并消除多达十分之九的住院治疗。”在一份声明中说。</blockquote></p><p> Infectious disease experts stress that preventing COVID-19 through wide use of vaccines remains the best way to control the pandemic, but only 58% of Americans are fully vaccinated and access in many parts of the world is limited.</p><p><blockquote>传染病专家强调，通过广泛使用疫苗来预防新冠肺炎仍然是控制疫情的最佳方式，但只有58%的美国人完全接种了疫苗，世界许多地区的疫苗接种有限。</blockquote></p><p> Pfizer's drug, part of a class known as protease inhibitors, is designed to block an enzyme the coronavirus needs in order to multiply.</p><p><blockquote>辉瑞的药物是蛋白酶抑制剂类药物的一部分，旨在阻断冠状病毒繁殖所需的酶。</blockquote></p><p> Merck's molnupiravir has a different mechanism of action designed to introduce errors into the genetic code of the virus. Merck has already sold millions of courses of the treatment, which was approved this week by U.K. regulators, to the United States, the U.K. and others.</p><p><blockquote>默克公司的molnupiravir具有不同的作用机制，旨在将错误引入病毒的遗传密码。默克公司已向美国、英国和其他国家出售了数百万个疗程的治疗药物，该药物本周获得了英国监管机构的批准。</blockquote></p><p> Britain said earlier this month it had secured 250,000 courses of Pfizer's antiviral.</p><p><blockquote>英国本月早些时候表示，已获得25万个疗程的辉瑞抗病毒药物。</blockquote></p><p> Pfizer is also studying whether its pill could be used by people without risk factors for serious COVID-19 as well as to prevent coronavirus infection in people exposed to the virus.</p><p><blockquote>辉瑞还在研究其药物是否可以被没有严重新冠肺炎风险因素的人使用，以及预防接触该病毒的人感染冠状病毒。</blockquote></p><p> Its&nbsp;shares&nbsp;rose&nbsp;over&nbsp;9%&nbsp;in&nbsp;premarket&nbsp;trading.<img src=\"https://static.tigerbbs.com/190a24394aa60d689cf29552569f5e20\" tg-width=\"774\" tg-height=\"567\" width=\"100%\" height=\"auto\"></p><p><blockquote>其股价在盘前交易中上涨超过9%。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer rose over 9% in premarket trading as its antiviral pill cut risk of severe COVID-19 by 89%<blockquote>辉瑞(Pfizer)在盘前交易中上涨超过9%，其抗病毒药物将严重COVID-19的风险降低了89%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer rose over 9% in premarket trading as its antiviral pill cut risk of severe COVID-19 by 89%<blockquote>辉瑞(Pfizer)在盘前交易中上涨超过9%，其抗病毒药物将严重COVID-19的风险降低了89%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-11-05 18:48</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>A trial of Pfizer Inc's experimental antiviral pill for COVID-19 was stopped early after the drug was shown to cut by 89% the chances of hospitalization or death for adults at risk of developing severe disease, the company said on Friday.</p><p><blockquote>辉瑞公司周五表示，该公司针对COVID-19的实验性抗病毒药物的试验提前停止，此前该药物被证明可以将有严重疾病风险的成年人住院或死亡的几率降低89%。</blockquote></p><p> The results appear to surpass those seen with Merck &amp; Co Inc's pill molnupiravir, which was shown last month to halve the likelihood of dying or being hospitalized for COVID-19 patients also at high risk of serious illness.</p><p><blockquote>这一结果似乎超过了默克公司(Merck&amp;Co Inc.)的药物molnupiravir的结果，该药物上个月被证明可以将同样具有严重疾病高风险的COVID-19患者死亡或住院的可能性减半。</blockquote></p><p> Full trial data is not yet available from either company.</p><p><blockquote>两家公司都尚未提供完整的试验数据。</blockquote></p><p> Pfizer said it plans to submit interim trial results for its pill, which is given in combination with an older antiviral called ritonavir, to the U.S. Food and Drug Administration as part of the emergency use application it opened in October.</p><p><blockquote>辉瑞表示，计划向美国提交其药物的中期试验结果，该药物与一种名为利托那韦的旧抗病毒药物联合使用。食品和药物管理局作为其10月份开放的紧急使用申请的一部分。</blockquote></p><p> The combination treatment, which will have the brand name Paxlovid, consists of three pills given twice daily.</p><p><blockquote>这种联合治疗的品牌名称为Paxlovid，包括每天两次服用三粒药丸。</blockquote></p><p> The planned analysis of 1,219 patients in Pfizer's study looked at hospitalizations or deaths among people diagnosed with mild to moderate COVID-19 with at least one risk factor for developing severe disease, such as obesity or older age.</p><p><blockquote>辉瑞研究中计划对1,219名患者进行分析，研究了被诊断患有轻度至中度COVID-19且至少有一种发展为严重疾病的风险因素（如肥胖或年龄较大）的人的住院或死亡情况。</blockquote></p><p> It found that 0.8% of those given Pfizer's drug within three days of symptom onset were hospitalized and none had died by 28 days after treatment. That compared with a hospitalization rate of 7% for placebo patients. There were also seven deaths in the placebo group.</p><p><blockquote>研究发现，在症状出现后三天内服用辉瑞药物的患者中，有0.8%住院治疗，没有人在治疗后28天内死亡。相比之下，安慰剂患者的住院率为7%。安慰剂组也有7例死亡。</blockquote></p><p> Rates were similar for patients treated within five days of symptoms - 1% of the treatment group was hospitalized, compared with 6.7% for the placebo group, which included 10 deaths.</p><p><blockquote>在出现症状5天内接受治疗的患者的比率相似——治疗组1%住院，而安慰剂组为6.7%，其中包括10例死亡。</blockquote></p><p> Antivirals need to be given as early as possible, before an infection takes hold, in order to be most effective. Merck tested its drug within five days of symptom onset.</p><p><blockquote>为了最有效，需要在感染发生之前尽早给予抗病毒药物。默克公司在症状出现后五天内测试了其药物。</blockquote></p><p> \"We saw that we did have high efficacy, even if it was five days after a patient has been treated ... people might wait a couple of days before getting a test or something, and this means that we have time to treat people and really provide a benefit from a public health perspective,\" Annaliesa Anderson, head of the Pfizer program, told Reuters.</p><p><blockquote>“我们发现我们确实具有很高的疗效，即使是在患者接受治疗五天后……人们可能会等待几天才能进行测试或其他事情，这意味着我们有时间治疗人们并从公共卫生的角度来看确实提供了好处，”辉瑞项目负责人安娜莉莎·安德森告诉路透社。</blockquote></p><p> The company did not detail side effects of the treatment, but said adverse events happened in about 20% of both treatment and placebo patients.</p><p><blockquote>该公司没有详细说明治疗的副作用，但表示约20%的治疗和安慰剂患者发生了不良事件。</blockquote></p><p> \"These data suggest that our oral antiviral candidate, if approved by regulatory authorities, has the potential to save patients’ lives, reduce the severity of COVID-19 infections, and eliminate up to nine out of ten hospitalizations,” Pfizer Chief Executive Albert Bourla said in a statement.</p><p><blockquote>辉瑞首席执行官Albert Bourla表示：“这些数据表明，我们的口服抗病毒候选药物如果获得监管机构的批准，有可能挽救患者的生命，降低COVID-19感染的严重程度，并消除多达十分之九的住院治疗。”在一份声明中说。</blockquote></p><p> Infectious disease experts stress that preventing COVID-19 through wide use of vaccines remains the best way to control the pandemic, but only 58% of Americans are fully vaccinated and access in many parts of the world is limited.</p><p><blockquote>传染病专家强调，通过广泛使用疫苗来预防新冠肺炎仍然是控制疫情的最佳方式，但只有58%的美国人完全接种了疫苗，世界许多地区的疫苗接种有限。</blockquote></p><p> Pfizer's drug, part of a class known as protease inhibitors, is designed to block an enzyme the coronavirus needs in order to multiply.</p><p><blockquote>辉瑞的药物是蛋白酶抑制剂类药物的一部分，旨在阻断冠状病毒繁殖所需的酶。</blockquote></p><p> Merck's molnupiravir has a different mechanism of action designed to introduce errors into the genetic code of the virus. Merck has already sold millions of courses of the treatment, which was approved this week by U.K. regulators, to the United States, the U.K. and others.</p><p><blockquote>默克公司的molnupiravir具有不同的作用机制，旨在将错误引入病毒的遗传密码。默克公司已向美国、英国和其他国家出售了数百万个疗程的治疗药物，该药物本周获得了英国监管机构的批准。</blockquote></p><p> Britain said earlier this month it had secured 250,000 courses of Pfizer's antiviral.</p><p><blockquote>英国本月早些时候表示，已获得25万个疗程的辉瑞抗病毒药物。</blockquote></p><p> Pfizer is also studying whether its pill could be used by people without risk factors for serious COVID-19 as well as to prevent coronavirus infection in people exposed to the virus.</p><p><blockquote>辉瑞还在研究其药物是否可以被没有严重新冠肺炎风险因素的人使用，以及预防接触该病毒的人感染冠状病毒。</blockquote></p><p> Its&nbsp;shares&nbsp;rose&nbsp;over&nbsp;9%&nbsp;in&nbsp;premarket&nbsp;trading.<img src=\"https://static.tigerbbs.com/190a24394aa60d689cf29552569f5e20\" tg-width=\"774\" tg-height=\"567\" width=\"100%\" height=\"auto\"></p><p><blockquote>其股价在盘前交易中上涨超过9%。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1168526565","content_text":"A trial of Pfizer Inc's experimental antiviral pill for COVID-19 was stopped early after the drug was shown to cut by 89% the chances of hospitalization or death for adults at risk of developing severe disease, the company said on Friday.\nThe results appear to surpass those seen with Merck & Co Inc's pill molnupiravir, which was shown last month to halve the likelihood of dying or being hospitalized for COVID-19 patients also at high risk of serious illness.\nFull trial data is not yet available from either company.\nPfizer said it plans to submit interim trial results for its pill, which is given in combination with an older antiviral called ritonavir, to the U.S. Food and Drug Administration as part of the emergency use application it opened in October.\nThe combination treatment, which will have the brand name Paxlovid, consists of three pills given twice daily.\nThe planned analysis of 1,219 patients in Pfizer's study looked at hospitalizations or deaths among people diagnosed with mild to moderate COVID-19 with at least one risk factor for developing severe disease, such as obesity or older age.\nIt found that 0.8% of those given Pfizer's drug within three days of symptom onset were hospitalized and none had died by 28 days after treatment. That compared with a hospitalization rate of 7% for placebo patients. There were also seven deaths in the placebo group.\nRates were similar for patients treated within five days of symptoms - 1% of the treatment group was hospitalized, compared with 6.7% for the placebo group, which included 10 deaths.\nAntivirals need to be given as early as possible, before an infection takes hold, in order to be most effective. Merck tested its drug within five days of symptom onset.\n\"We saw that we did have high efficacy, even if it was five days after a patient has been treated ... people might wait a couple of days before getting a test or something, and this means that we have time to treat people and really provide a benefit from a public health perspective,\" Annaliesa Anderson, head of the Pfizer program, told Reuters.\nThe company did not detail side effects of the treatment, but said adverse events happened in about 20% of both treatment and placebo patients.\n\"These data suggest that our oral antiviral candidate, if approved by regulatory authorities, has the potential to save patients’ lives, reduce the severity of COVID-19 infections, and eliminate up to nine out of ten hospitalizations,” Pfizer Chief Executive Albert Bourla said in a statement.\nInfectious disease experts stress that preventing COVID-19 through wide use of vaccines remains the best way to control the pandemic, but only 58% of Americans are fully vaccinated and access in many parts of the world is limited.\nPfizer's drug, part of a class known as protease inhibitors, is designed to block an enzyme the coronavirus needs in order to multiply.\nMerck's molnupiravir has a different mechanism of action designed to introduce errors into the genetic code of the virus. Merck has already sold millions of courses of the treatment, which was approved this week by U.K. regulators, to the United States, the U.K. and others.\nBritain said earlier this month it had secured 250,000 courses of Pfizer's antiviral.\nPfizer is also studying whether its pill could be used by people without risk factors for serious COVID-19 as well as to prevent coronavirus infection in people exposed to the virus.\nIts shares rose over 9% in premarket trading.","news_type":1,"symbols_score_info":{"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":2681,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":846798097,"gmtCreate":1636111622666,"gmtModify":1636111622737,"author":{"id":"3574940915326235","authorId":"3574940915326235","name":"TheMysTrader","avatar":"https://static.tigerbbs.com/08abc512620038ac153ab0bf62705216","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574940915326235","idStr":"3574940915326235"},"themes":[],"htmlText":"Omg that's good news!&nbsp;","listText":"Omg that's good news!&nbsp;","text":"Omg that's good news!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/846798097","repostId":"1168526565","repostType":2,"repost":{"id":"1168526565","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1636109309,"share":"https://www.laohu8.com/m/news/1168526565?lang=zh_CN&edition=full","pubTime":"2021-11-05 18:48","market":"us","language":"en","title":"Pfizer rose over 9% in premarket trading as its antiviral pill cut risk of severe COVID-19 by 89%<blockquote>辉瑞(Pfizer)在盘前交易中上涨超过9%，其抗病毒药物将严重COVID-19的风险降低了89%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1168526565","media":"Tiger Newspress","summary":"A trial of Pfizer Inc's experimental antiviral pill for COVID-19 was stopped early after the drug wa","content":"<p>A trial of Pfizer Inc's experimental antiviral pill for COVID-19 was stopped early after the drug was shown to cut by 89% the chances of hospitalization or death for adults at risk of developing severe disease, the company said on Friday.</p><p><blockquote>辉瑞公司周五表示，该公司针对COVID-19的实验性抗病毒药物的试验提前停止，此前该药物被证明可以将有严重疾病风险的成年人住院或死亡的几率降低89%。</blockquote></p><p> The results appear to surpass those seen with Merck &amp; Co Inc's pill molnupiravir, which was shown last month to halve the likelihood of dying or being hospitalized for COVID-19 patients also at high risk of serious illness.</p><p><blockquote>这一结果似乎超过了默克公司(Merck&amp;Co Inc.)的药物molnupiravir的结果，该药物上个月被证明可以将同样具有严重疾病高风险的COVID-19患者死亡或住院的可能性减半。</blockquote></p><p> Full trial data is not yet available from either company.</p><p><blockquote>两家公司都尚未提供完整的试验数据。</blockquote></p><p> Pfizer said it plans to submit interim trial results for its pill, which is given in combination with an older antiviral called ritonavir, to the U.S. Food and Drug Administration as part of the emergency use application it opened in October.</p><p><blockquote>辉瑞表示，计划向美国提交其药物的中期试验结果，该药物与一种名为利托那韦的旧抗病毒药物联合使用。食品和药物管理局作为其10月份开放的紧急使用申请的一部分。</blockquote></p><p> The combination treatment, which will have the brand name Paxlovid, consists of three pills given twice daily.</p><p><blockquote>这种联合治疗的品牌名称为Paxlovid，包括每天两次服用三粒药丸。</blockquote></p><p> The planned analysis of 1,219 patients in Pfizer's study looked at hospitalizations or deaths among people diagnosed with mild to moderate COVID-19 with at least one risk factor for developing severe disease, such as obesity or older age.</p><p><blockquote>辉瑞研究中计划对1,219名患者进行分析，研究了被诊断患有轻度至中度COVID-19且至少有一种发展为严重疾病的风险因素（如肥胖或年龄较大）的人的住院或死亡情况。</blockquote></p><p> It found that 0.8% of those given Pfizer's drug within three days of symptom onset were hospitalized and none had died by 28 days after treatment. That compared with a hospitalization rate of 7% for placebo patients. There were also seven deaths in the placebo group.</p><p><blockquote>研究发现，在症状出现后三天内服用辉瑞药物的患者中，有0.8%住院治疗，没有人在治疗后28天内死亡。相比之下，安慰剂患者的住院率为7%。安慰剂组也有7例死亡。</blockquote></p><p> Rates were similar for patients treated within five days of symptoms - 1% of the treatment group was hospitalized, compared with 6.7% for the placebo group, which included 10 deaths.</p><p><blockquote>在出现症状5天内接受治疗的患者的比率相似——治疗组1%住院，而安慰剂组为6.7%，其中包括10例死亡。</blockquote></p><p> Antivirals need to be given as early as possible, before an infection takes hold, in order to be most effective. Merck tested its drug within five days of symptom onset.</p><p><blockquote>为了最有效，需要在感染发生之前尽早给予抗病毒药物。默克公司在症状出现后五天内测试了其药物。</blockquote></p><p> \"We saw that we did have high efficacy, even if it was five days after a patient has been treated ... people might wait a couple of days before getting a test or something, and this means that we have time to treat people and really provide a benefit from a public health perspective,\" Annaliesa Anderson, head of the Pfizer program, told Reuters.</p><p><blockquote>“我们发现我们确实具有很高的疗效，即使是在患者接受治疗五天后……人们可能会等待几天才能进行测试或其他事情，这意味着我们有时间治疗人们并从公共卫生的角度来看确实提供了好处，”辉瑞项目负责人安娜莉莎·安德森告诉路透社。</blockquote></p><p> The company did not detail side effects of the treatment, but said adverse events happened in about 20% of both treatment and placebo patients.</p><p><blockquote>该公司没有详细说明治疗的副作用，但表示约20%的治疗和安慰剂患者发生了不良事件。</blockquote></p><p> \"These data suggest that our oral antiviral candidate, if approved by regulatory authorities, has the potential to save patients’ lives, reduce the severity of COVID-19 infections, and eliminate up to nine out of ten hospitalizations,” Pfizer Chief Executive Albert Bourla said in a statement.</p><p><blockquote>辉瑞首席执行官Albert Bourla表示：“这些数据表明，我们的口服抗病毒候选药物如果获得监管机构的批准，有可能挽救患者的生命，降低COVID-19感染的严重程度，并消除多达十分之九的住院治疗。”在一份声明中说。</blockquote></p><p> Infectious disease experts stress that preventing COVID-19 through wide use of vaccines remains the best way to control the pandemic, but only 58% of Americans are fully vaccinated and access in many parts of the world is limited.</p><p><blockquote>传染病专家强调，通过广泛使用疫苗来预防新冠肺炎仍然是控制疫情的最佳方式，但只有58%的美国人完全接种了疫苗，世界许多地区的疫苗接种有限。</blockquote></p><p> Pfizer's drug, part of a class known as protease inhibitors, is designed to block an enzyme the coronavirus needs in order to multiply.</p><p><blockquote>辉瑞的药物是蛋白酶抑制剂类药物的一部分，旨在阻断冠状病毒繁殖所需的酶。</blockquote></p><p> Merck's molnupiravir has a different mechanism of action designed to introduce errors into the genetic code of the virus. Merck has already sold millions of courses of the treatment, which was approved this week by U.K. regulators, to the United States, the U.K. and others.</p><p><blockquote>默克公司的molnupiravir具有不同的作用机制，旨在将错误引入病毒的遗传密码。默克公司已向美国、英国和其他国家出售了数百万个疗程的治疗药物，该药物本周获得了英国监管机构的批准。</blockquote></p><p> Britain said earlier this month it had secured 250,000 courses of Pfizer's antiviral.</p><p><blockquote>英国本月早些时候表示，已获得25万个疗程的辉瑞抗病毒药物。</blockquote></p><p> Pfizer is also studying whether its pill could be used by people without risk factors for serious COVID-19 as well as to prevent coronavirus infection in people exposed to the virus.</p><p><blockquote>辉瑞还在研究其药物是否可以被没有严重新冠肺炎风险因素的人使用，以及预防接触该病毒的人感染冠状病毒。</blockquote></p><p> Its&nbsp;shares&nbsp;rose&nbsp;over&nbsp;9%&nbsp;in&nbsp;premarket&nbsp;trading.<img src=\"https://static.tigerbbs.com/190a24394aa60d689cf29552569f5e20\" tg-width=\"774\" tg-height=\"567\" width=\"100%\" height=\"auto\"></p><p><blockquote>其股价在盘前交易中上涨超过9%。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer rose over 9% in premarket trading as its antiviral pill cut risk of severe COVID-19 by 89%<blockquote>辉瑞(Pfizer)在盘前交易中上涨超过9%，其抗病毒药物将严重COVID-19的风险降低了89%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer rose over 9% in premarket trading as its antiviral pill cut risk of severe COVID-19 by 89%<blockquote>辉瑞(Pfizer)在盘前交易中上涨超过9%，其抗病毒药物将严重COVID-19的风险降低了89%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-11-05 18:48</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>A trial of Pfizer Inc's experimental antiviral pill for COVID-19 was stopped early after the drug was shown to cut by 89% the chances of hospitalization or death for adults at risk of developing severe disease, the company said on Friday.</p><p><blockquote>辉瑞公司周五表示，该公司针对COVID-19的实验性抗病毒药物的试验提前停止，此前该药物被证明可以将有严重疾病风险的成年人住院或死亡的几率降低89%。</blockquote></p><p> The results appear to surpass those seen with Merck &amp; Co Inc's pill molnupiravir, which was shown last month to halve the likelihood of dying or being hospitalized for COVID-19 patients also at high risk of serious illness.</p><p><blockquote>这一结果似乎超过了默克公司(Merck&amp;Co Inc.)的药物molnupiravir的结果，该药物上个月被证明可以将同样具有严重疾病高风险的COVID-19患者死亡或住院的可能性减半。</blockquote></p><p> Full trial data is not yet available from either company.</p><p><blockquote>两家公司都尚未提供完整的试验数据。</blockquote></p><p> Pfizer said it plans to submit interim trial results for its pill, which is given in combination with an older antiviral called ritonavir, to the U.S. Food and Drug Administration as part of the emergency use application it opened in October.</p><p><blockquote>辉瑞表示，计划向美国提交其药物的中期试验结果，该药物与一种名为利托那韦的旧抗病毒药物联合使用。食品和药物管理局作为其10月份开放的紧急使用申请的一部分。</blockquote></p><p> The combination treatment, which will have the brand name Paxlovid, consists of three pills given twice daily.</p><p><blockquote>这种联合治疗的品牌名称为Paxlovid，包括每天两次服用三粒药丸。</blockquote></p><p> The planned analysis of 1,219 patients in Pfizer's study looked at hospitalizations or deaths among people diagnosed with mild to moderate COVID-19 with at least one risk factor for developing severe disease, such as obesity or older age.</p><p><blockquote>辉瑞研究中计划对1,219名患者进行分析，研究了被诊断患有轻度至中度COVID-19且至少有一种发展为严重疾病的风险因素（如肥胖或年龄较大）的人的住院或死亡情况。</blockquote></p><p> It found that 0.8% of those given Pfizer's drug within three days of symptom onset were hospitalized and none had died by 28 days after treatment. That compared with a hospitalization rate of 7% for placebo patients. There were also seven deaths in the placebo group.</p><p><blockquote>研究发现，在症状出现后三天内服用辉瑞药物的患者中，有0.8%住院治疗，没有人在治疗后28天内死亡。相比之下，安慰剂患者的住院率为7%。安慰剂组也有7例死亡。</blockquote></p><p> Rates were similar for patients treated within five days of symptoms - 1% of the treatment group was hospitalized, compared with 6.7% for the placebo group, which included 10 deaths.</p><p><blockquote>在出现症状5天内接受治疗的患者的比率相似——治疗组1%住院，而安慰剂组为6.7%，其中包括10例死亡。</blockquote></p><p> Antivirals need to be given as early as possible, before an infection takes hold, in order to be most effective. Merck tested its drug within five days of symptom onset.</p><p><blockquote>为了最有效，需要在感染发生之前尽早给予抗病毒药物。默克公司在症状出现后五天内测试了其药物。</blockquote></p><p> \"We saw that we did have high efficacy, even if it was five days after a patient has been treated ... people might wait a couple of days before getting a test or something, and this means that we have time to treat people and really provide a benefit from a public health perspective,\" Annaliesa Anderson, head of the Pfizer program, told Reuters.</p><p><blockquote>“我们发现我们确实具有很高的疗效，即使是在患者接受治疗五天后……人们可能会等待几天才能进行测试或其他事情，这意味着我们有时间治疗人们并从公共卫生的角度来看确实提供了好处，”辉瑞项目负责人安娜莉莎·安德森告诉路透社。</blockquote></p><p> The company did not detail side effects of the treatment, but said adverse events happened in about 20% of both treatment and placebo patients.</p><p><blockquote>该公司没有详细说明治疗的副作用，但表示约20%的治疗和安慰剂患者发生了不良事件。</blockquote></p><p> \"These data suggest that our oral antiviral candidate, if approved by regulatory authorities, has the potential to save patients’ lives, reduce the severity of COVID-19 infections, and eliminate up to nine out of ten hospitalizations,” Pfizer Chief Executive Albert Bourla said in a statement.</p><p><blockquote>辉瑞首席执行官Albert Bourla表示：“这些数据表明，我们的口服抗病毒候选药物如果获得监管机构的批准，有可能挽救患者的生命，降低COVID-19感染的严重程度，并消除多达十分之九的住院治疗。”在一份声明中说。</blockquote></p><p> Infectious disease experts stress that preventing COVID-19 through wide use of vaccines remains the best way to control the pandemic, but only 58% of Americans are fully vaccinated and access in many parts of the world is limited.</p><p><blockquote>传染病专家强调，通过广泛使用疫苗来预防新冠肺炎仍然是控制疫情的最佳方式，但只有58%的美国人完全接种了疫苗，世界许多地区的疫苗接种有限。</blockquote></p><p> Pfizer's drug, part of a class known as protease inhibitors, is designed to block an enzyme the coronavirus needs in order to multiply.</p><p><blockquote>辉瑞的药物是蛋白酶抑制剂类药物的一部分，旨在阻断冠状病毒繁殖所需的酶。</blockquote></p><p> Merck's molnupiravir has a different mechanism of action designed to introduce errors into the genetic code of the virus. Merck has already sold millions of courses of the treatment, which was approved this week by U.K. regulators, to the United States, the U.K. and others.</p><p><blockquote>默克公司的molnupiravir具有不同的作用机制，旨在将错误引入病毒的遗传密码。默克公司已向美国、英国和其他国家出售了数百万个疗程的治疗药物，该药物本周获得了英国监管机构的批准。</blockquote></p><p> Britain said earlier this month it had secured 250,000 courses of Pfizer's antiviral.</p><p><blockquote>英国本月早些时候表示，已获得25万个疗程的辉瑞抗病毒药物。</blockquote></p><p> Pfizer is also studying whether its pill could be used by people without risk factors for serious COVID-19 as well as to prevent coronavirus infection in people exposed to the virus.</p><p><blockquote>辉瑞还在研究其药物是否可以被没有严重新冠肺炎风险因素的人使用，以及预防接触该病毒的人感染冠状病毒。</blockquote></p><p> Its&nbsp;shares&nbsp;rose&nbsp;over&nbsp;9%&nbsp;in&nbsp;premarket&nbsp;trading.<img src=\"https://static.tigerbbs.com/190a24394aa60d689cf29552569f5e20\" tg-width=\"774\" tg-height=\"567\" width=\"100%\" height=\"auto\"></p><p><blockquote>其股价在盘前交易中上涨超过9%。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1168526565","content_text":"A trial of Pfizer Inc's experimental antiviral pill for COVID-19 was stopped early after the drug was shown to cut by 89% the chances of hospitalization or death for adults at risk of developing severe disease, the company said on Friday.\nThe results appear to surpass those seen with Merck & Co Inc's pill molnupiravir, which was shown last month to halve the likelihood of dying or being hospitalized for COVID-19 patients also at high risk of serious illness.\nFull trial data is not yet available from either company.\nPfizer said it plans to submit interim trial results for its pill, which is given in combination with an older antiviral called ritonavir, to the U.S. Food and Drug Administration as part of the emergency use application it opened in October.\nThe combination treatment, which will have the brand name Paxlovid, consists of three pills given twice daily.\nThe planned analysis of 1,219 patients in Pfizer's study looked at hospitalizations or deaths among people diagnosed with mild to moderate COVID-19 with at least one risk factor for developing severe disease, such as obesity or older age.\nIt found that 0.8% of those given Pfizer's drug within three days of symptom onset were hospitalized and none had died by 28 days after treatment. That compared with a hospitalization rate of 7% for placebo patients. There were also seven deaths in the placebo group.\nRates were similar for patients treated within five days of symptoms - 1% of the treatment group was hospitalized, compared with 6.7% for the placebo group, which included 10 deaths.\nAntivirals need to be given as early as possible, before an infection takes hold, in order to be most effective. Merck tested its drug within five days of symptom onset.\n\"We saw that we did have high efficacy, even if it was five days after a patient has been treated ... people might wait a couple of days before getting a test or something, and this means that we have time to treat people and really provide a benefit from a public health perspective,\" Annaliesa Anderson, head of the Pfizer program, told Reuters.\nThe company did not detail side effects of the treatment, but said adverse events happened in about 20% of both treatment and placebo patients.\n\"These data suggest that our oral antiviral candidate, if approved by regulatory authorities, has the potential to save patients’ lives, reduce the severity of COVID-19 infections, and eliminate up to nine out of ten hospitalizations,” Pfizer Chief Executive Albert Bourla said in a statement.\nInfectious disease experts stress that preventing COVID-19 through wide use of vaccines remains the best way to control the pandemic, but only 58% of Americans are fully vaccinated and access in many parts of the world is limited.\nPfizer's drug, part of a class known as protease inhibitors, is designed to block an enzyme the coronavirus needs in order to multiply.\nMerck's molnupiravir has a different mechanism of action designed to introduce errors into the genetic code of the virus. Merck has already sold millions of courses of the treatment, which was approved this week by U.K. regulators, to the United States, the U.K. and others.\nBritain said earlier this month it had secured 250,000 courses of Pfizer's antiviral.\nPfizer is also studying whether its pill could be used by people without risk factors for serious COVID-19 as well as to prevent coronavirus infection in people exposed to the virus.\nIts shares rose over 9% in premarket trading.","news_type":1,"symbols_score_info":{"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":2625,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":600554198,"gmtCreate":1638178262115,"gmtModify":1638178262281,"author":{"id":"3574940915326235","authorId":"3574940915326235","name":"TheMysTrader","avatar":"https://static.tigerbbs.com/08abc512620038ac153ab0bf62705216","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574940915326235","idStr":"3574940915326235"},"themes":[],"htmlText":"Will tesla 🚀 to a whole new level?","listText":"Will tesla 🚀 to a whole new level?","text":"Will tesla 🚀 to a whole new level?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/600554198","repostId":"1180553445","repostType":4,"repost":{"id":"1180553445","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638177356,"share":"https://www.laohu8.com/m/news/1180553445?lang=zh_CN&edition=full","pubTime":"2021-11-29 17:15","market":"us","language":"en","title":"Tesla stock rallied nearly 3% in premarket trading<blockquote>特斯拉股价在盘前交易中上涨近3%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1180553445","media":"Tiger Newspress","summary":"Tesla stock rallied nearly 3% in premarket trading as it to start production in Germany in December,","content":"<p>Tesla stock rallied nearly&nbsp;3% in premarket trading&nbsp;as&nbsp;it to start production in Germany in December,according to&nbsp;Automobilwoche.</p><p><blockquote>据Automobilwoche报道，特斯拉股价在盘前交易中上涨近3%，该公司将于12月在德国开始生产。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/c924dd7ad062e13f25605d196e86462b\" tg-width=\"853\" tg-height=\"619\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p> Tesla Inc. will launch its overdue German production operations in December, Automobilwoche reported, estimating as many as 30,000 vehicles will be manufactured there in the first half of 2022.</p><p><blockquote>据Automobilwoche报道，特斯拉公司将于12月启动其迟来的德国生产业务，预计2022年上半年德国将生产多达30,000辆汽车。</blockquote></p><p> Production was to have begun in July but was delayed because the company hadn’t received environmental clearance. Local regulators are expected to grant the necessary permits within days, the magazine said, without reporting where it received its information.</p><p><blockquote>生产原定于7月开始，但由于该公司尚未获得环境许可而被推迟。该杂志称，当地监管机构预计将在几天内授予必要的许可，但没有报告从哪里收到信息。</blockquote></p><p> Five units of Model Y have already been completed at the Gigafactory near Berlin, though not on the production line. In January, serial production will start with 1,000 cars per week and gradually increase, according to Automobilwoche.</p><p><blockquote>柏林附近的超级工厂已经完成了五台Model Y，但尚未上生产线。据Automobilwoche称，1月份，批量生产将从每周1,000辆汽车开始，并逐渐增加。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tesla stock rallied nearly 3% in premarket trading<blockquote>特斯拉股价在盘前交易中上涨近3%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTesla stock rallied nearly 3% in premarket trading<blockquote>特斯拉股价在盘前交易中上涨近3%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-11-29 17:15</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Tesla stock rallied nearly&nbsp;3% in premarket trading&nbsp;as&nbsp;it to start production in Germany in December,according to&nbsp;Automobilwoche.</p><p><blockquote>据Automobilwoche报道，特斯拉股价在盘前交易中上涨近3%，该公司将于12月在德国开始生产。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/c924dd7ad062e13f25605d196e86462b\" tg-width=\"853\" tg-height=\"619\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p> Tesla Inc. will launch its overdue German production operations in December, Automobilwoche reported, estimating as many as 30,000 vehicles will be manufactured there in the first half of 2022.</p><p><blockquote>据Automobilwoche报道，特斯拉公司将于12月启动其迟来的德国生产业务，预计2022年上半年德国将生产多达30,000辆汽车。</blockquote></p><p> Production was to have begun in July but was delayed because the company hadn’t received environmental clearance. Local regulators are expected to grant the necessary permits within days, the magazine said, without reporting where it received its information.</p><p><blockquote>生产原定于7月开始，但由于该公司尚未获得环境许可而被推迟。该杂志称，当地监管机构预计将在几天内授予必要的许可，但没有报告从哪里收到信息。</blockquote></p><p> Five units of Model Y have already been completed at the Gigafactory near Berlin, though not on the production line. In January, serial production will start with 1,000 cars per week and gradually increase, according to Automobilwoche.</p><p><blockquote>柏林附近的超级工厂已经完成了五台Model Y，但尚未上生产线。据Automobilwoche称，1月份，批量生产将从每周1,000辆汽车开始，并逐渐增加。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1180553445","content_text":"Tesla stock rallied nearly 3% in premarket trading as it to start production in Germany in December,according to Automobilwoche.\n\nTesla Inc. will launch its overdue German production operations in December, Automobilwoche reported, estimating as many as 30,000 vehicles will be manufactured there in the first half of 2022.\nProduction was to have begun in July but was delayed because the company hadn’t received environmental clearance. Local regulators are expected to grant the necessary permits within days, the magazine said, without reporting where it received its information.\nFive units of Model Y have already been completed at the Gigafactory near Berlin, though not on the production line. In January, serial production will start with 1,000 cars per week and gradually increase, according to Automobilwoche.","news_type":1,"symbols_score_info":{"TSLA":0.9}},"isVote":1,"tweetType":1,"viewCount":2001,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":877561413,"gmtCreate":1637944348124,"gmtModify":1637944348124,"author":{"id":"3574940915326235","authorId":"3574940915326235","name":"TheMysTrader","avatar":"https://static.tigerbbs.com/08abc512620038ac153ab0bf62705216","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574940915326235","idStr":"3574940915326235"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SE\">$Sea Ltd(SE)$</a>&nbsp;awww where's the last hr sales","listText":"<a href=\"https://laohu8.com/S/SE\">$Sea Ltd(SE)$</a>&nbsp;awww where's the last hr sales","text":"$Sea Ltd(SE)$ awww where's the last hr sales","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/877561413","isVote":1,"tweetType":1,"viewCount":2308,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":853937233,"gmtCreate":1634755270098,"gmtModify":1634755270227,"author":{"id":"3574940915326235","authorId":"3574940915326235","name":"TheMysTrader","avatar":"https://static.tigerbbs.com/08abc512620038ac153ab0bf62705216","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574940915326235","idStr":"3574940915326235"},"themes":[],"htmlText":"Will&nbsp;<a href=\"https://laohu8.com/S/TSLA\">$Tesla Motors(TSLA)$</a>hit 900 alike earlier part of the year?&nbsp;","listText":"Will&nbsp;<a href=\"https://laohu8.com/S/TSLA\">$Tesla Motors(TSLA)$</a>hit 900 alike earlier part of the year?&nbsp;","text":"Will $Tesla Motors(TSLA)$hit 900 alike earlier part of the year?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/853937233","isVote":1,"tweetType":1,"viewCount":1927,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":846711921,"gmtCreate":1636113379725,"gmtModify":1636113503105,"author":{"id":"3574940915326235","authorId":"3574940915326235","name":"TheMysTrader","avatar":"https://static.tigerbbs.com/08abc512620038ac153ab0bf62705216","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574940915326235","idStr":"3574940915326235"},"themes":[],"htmlText":"Buy the slid wheee","listText":"Buy the slid wheee","text":"Buy the slid wheee","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/846711921","repostId":"1136485403","repostType":2,"isVote":1,"tweetType":1,"viewCount":2140,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":128865013,"gmtCreate":1624510533832,"gmtModify":1634005038213,"author":{"id":"3574940915326235","authorId":"3574940915326235","name":"TheMysTrader","avatar":"https://static.tigerbbs.com/08abc512620038ac153ab0bf62705216","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574940915326235","idStr":"3574940915326235"},"themes":[],"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/128865013","repostId":"1170004118","repostType":4,"isVote":1,"tweetType":1,"viewCount":1341,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":128868955,"gmtCreate":1624510444177,"gmtModify":1634005040737,"author":{"id":"3574940915326235","authorId":"3574940915326235","name":"TheMysTrader","avatar":"https://static.tigerbbs.com/08abc512620038ac153ab0bf62705216","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574940915326235","idStr":"3574940915326235"},"themes":[],"htmlText":"Bbtea ❤️","listText":"Bbtea ❤️","text":"Bbtea ❤️","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/128868955","repostId":"1178700711","repostType":4,"repost":{"id":"1178700711","kind":"news","pubTimestamp":1624497882,"share":"https://www.laohu8.com/m/news/1178700711?lang=zh_CN&edition=full","pubTime":"2021-06-24 09:24","market":"hk","language":"en","title":"Bubble Tea Chain Raises $656 Million in Hong Kong IPO<blockquote>珍珠奶茶连锁店香港IPO融资6.56亿美元</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1178700711","media":"Bloomberg","summary":"(Bloomberg) -- Chinese bubble tea chain Nayuki Holdings Ltd. has raised HK$5.09 billion ($656 millio","content":"<p>(Bloomberg) -- Chinese bubble tea chain Nayuki Holdings Ltd. has raised HK$5.09 billion ($656 million) after pricing its Hong Kong initial public offering at the top of a marketed range, the latest company to ride a resurgence of listings in the Asian financial hub.</p><p><blockquote>（彭博社）-中国珍珠奶茶连锁店奈雪控股有限公司在香港首次公开募股定价高于市场范围后，筹集了50.9亿港元（6.56亿美元），这是最新一家在亚洲金融中心上市复苏的公司。</blockquote></p><p> Nayuki, whose popular fresh-fruit teas include cheese-foam-topped beverages, has priced 257.3 million shares at HK$19.8 each, according to terms of the deal obtained by Bloomberg News. It had marketed the shares at HK$17.2 to HK$19.8 apiece.</p><p><blockquote>根据彭博新闻社获得的交易条款，奈雪的受欢迎的鲜果茶包括芝士泡沫饮料，该公司以每股19.8港元的价格发行了2.573亿股股票。该公司以每股17.2港元至19.8港元的价格出售股份。</blockquote></p><p> The teahouse operator is testing the waters after Angelalign Technology Inc., a maker of clear orthodontic braces, heralded a revival in Hong Kong’s IPO market with a massive 132% pop on its June 16 debut, becoming one of this year’s most popular offerings in the city.</p><p><blockquote>透明正畸牙套制造商时代天使科技公司(Angelalign Technology Inc.)在6月16日首次亮相时股价飙升132%，成为今年香港最受欢迎的产品之一，预示着香港IPO市场的复苏，这家茶馆运营商正在试水。</blockquote></p><p> First-time share sales in Hong Kong are ticking up after a period of muted activity, as an easing of the global tech selloff has created a more favorable backdrop for debuts. At least 13 companies are currently in the lineup to go public, compared to only two deals priced in April and four in May, according to data compiled by Bloomberg.</p><p><blockquote>在经历了一段时间的低迷活动后，香港的首次公开募股销售正在回升，因为全球科技股抛售的缓解为首次公开募股创造了更有利的背景。根据彭博社汇编的数据，目前至少有13家公司正在准备上市，而4月份只有两笔交易定价，5月份有四笔交易定价。</blockquote></p><p> Still, not every IPO is getting a warm welcome as investors have become more selective amid higher volatility in markets and growing expectations of a tightening of U.S. monetary policy. China Youran Dairy Group Ltd. and CARsgen Therapeutics Holdings Ltd. slumped 12% and 9%, respectively, in their trading debuts last Friday.</p><p><blockquote>尽管如此，并非每一次IPO都受到热烈欢迎，因为在市场波动加剧和对美国货币政策收紧的预期不断增强的情况下，投资者变得更加挑剔。中国优然乳业集团有限公司和科济药业控股有限公司上周五首次上市时分别下跌12%和9%。</blockquote></p><p> Nayuki’s share sale attracted five cornerstone investors who agreed to subscribe for about $155 million of stock. They are UBS Asset Management, China Universal Asset Management, GF Fund, China Southern Asset Management and CCB International, according to the prospectus.</p><p><blockquote>奈雪的股票出售吸引了五名基石投资者，他们同意认购约1.55亿美元的股票。根据招股说明书，它们是瑞银资产管理、汇添富资产管理、广发基金、南方基金和建银国际。</blockquote></p><p> The retail portion of Nayuki’s IPO was more than 400 times oversubscribed, the Hong Kong Economic Journal reported, citing people it didn’t identify.</p><p><blockquote>据《信报》援引未透露姓名的人士报道，奈雪的IPO零售部分超额认购超过400倍。</blockquote></p><p> The top-of-the-range pricing values the bubble tea chain at about $4.38 billion, up from the $2 billion in its last funding round. It originally planned to file for an IPO in the U.S. in February last year, Bloomberg News reported, but eventually opted for Hong Kong.</p><p><blockquote>顶级定价对这家珍珠奶茶连锁店的估值约为43.8亿美元，高于上一轮融资的20亿美元。据彭博社报道，该公司最初计划于去年2月在美国申请IPO，但最终选择了香港。</blockquote></p><p> The Shenzhen-based firm sells fresh-fruit teas, cold-brew beverages and baked goods. It recorded losses of 203 million yuan in 2020 and 40 million yuan in the previous year, according to its prospectus. Revenue rose 22% year-on-year to 3.1 billion yuan.</p><p><blockquote>这家总部位于深圳的公司销售鲜果茶、冷饮和烘焙食品。招股书显示，该公司2020年亏损2.03亿元，上年亏损4000万元。营收同比升22%至31亿元。</blockquote></p><p> Nayuki plans to use proceeds from the offering to expand its teahouse network, deepen market penetration and strengthen its supply chain. It had 491 flagship Nayuki outlets at the end of last year, including 489 in mainland China and one each in Hong Kong and Japan.</p><p><blockquote>奈雪计划将此次发行所得用于扩大其茶馆网络、深化市场渗透并加强其供应链。截至去年底，其拥有491家奈雪旗舰店，其中中国内地489家，香港和日本各1家。</blockquote></p><p> Nayuki’s shares are set to start trading in Hong Kong on June 30. JPMorgan Chase &amp; Co., CMB International Capital Ltd. and Huatai International Ltd. are joint sponsors for the listing.</p><p><blockquote>奈雪的股票定于6月30日在香港开始交易。摩根大通、招银国际金融有限公司及华泰国际有限公司为本次上市的联席保荐人。</blockquote></p><p></p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bubble Tea Chain Raises $656 Million in Hong Kong IPO<blockquote>珍珠奶茶连锁店香港IPO融资6.56亿美元</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBubble Tea Chain Raises $656 Million in Hong Kong IPO<blockquote>珍珠奶茶连锁店香港IPO融资6.56亿美元</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Bloomberg</strong><span class=\"h-time small\">2021-06-24 09:24</span>\n</p>\n</h4>\n</header>\n<article>\n<p>(Bloomberg) -- Chinese bubble tea chain Nayuki Holdings Ltd. has raised HK$5.09 billion ($656 million) after pricing its Hong Kong initial public offering at the top of a marketed range, the latest company to ride a resurgence of listings in the Asian financial hub.</p><p><blockquote>（彭博社）-中国珍珠奶茶连锁店奈雪控股有限公司在香港首次公开募股定价高于市场范围后，筹集了50.9亿港元（6.56亿美元），这是最新一家在亚洲金融中心上市复苏的公司。</blockquote></p><p> Nayuki, whose popular fresh-fruit teas include cheese-foam-topped beverages, has priced 257.3 million shares at HK$19.8 each, according to terms of the deal obtained by Bloomberg News. It had marketed the shares at HK$17.2 to HK$19.8 apiece.</p><p><blockquote>根据彭博新闻社获得的交易条款，奈雪的受欢迎的鲜果茶包括芝士泡沫饮料，该公司以每股19.8港元的价格发行了2.573亿股股票。该公司以每股17.2港元至19.8港元的价格出售股份。</blockquote></p><p> The teahouse operator is testing the waters after Angelalign Technology Inc., a maker of clear orthodontic braces, heralded a revival in Hong Kong’s IPO market with a massive 132% pop on its June 16 debut, becoming one of this year’s most popular offerings in the city.</p><p><blockquote>透明正畸牙套制造商时代天使科技公司(Angelalign Technology Inc.)在6月16日首次亮相时股价飙升132%，成为今年香港最受欢迎的产品之一，预示着香港IPO市场的复苏，这家茶馆运营商正在试水。</blockquote></p><p> First-time share sales in Hong Kong are ticking up after a period of muted activity, as an easing of the global tech selloff has created a more favorable backdrop for debuts. At least 13 companies are currently in the lineup to go public, compared to only two deals priced in April and four in May, according to data compiled by Bloomberg.</p><p><blockquote>在经历了一段时间的低迷活动后，香港的首次公开募股销售正在回升，因为全球科技股抛售的缓解为首次公开募股创造了更有利的背景。根据彭博社汇编的数据，目前至少有13家公司正在准备上市，而4月份只有两笔交易定价，5月份有四笔交易定价。</blockquote></p><p> Still, not every IPO is getting a warm welcome as investors have become more selective amid higher volatility in markets and growing expectations of a tightening of U.S. monetary policy. China Youran Dairy Group Ltd. and CARsgen Therapeutics Holdings Ltd. slumped 12% and 9%, respectively, in their trading debuts last Friday.</p><p><blockquote>尽管如此，并非每一次IPO都受到热烈欢迎，因为在市场波动加剧和对美国货币政策收紧的预期不断增强的情况下，投资者变得更加挑剔。中国优然乳业集团有限公司和科济药业控股有限公司上周五首次上市时分别下跌12%和9%。</blockquote></p><p> Nayuki’s share sale attracted five cornerstone investors who agreed to subscribe for about $155 million of stock. They are UBS Asset Management, China Universal Asset Management, GF Fund, China Southern Asset Management and CCB International, according to the prospectus.</p><p><blockquote>奈雪的股票出售吸引了五名基石投资者，他们同意认购约1.55亿美元的股票。根据招股说明书，它们是瑞银资产管理、汇添富资产管理、广发基金、南方基金和建银国际。</blockquote></p><p> The retail portion of Nayuki’s IPO was more than 400 times oversubscribed, the Hong Kong Economic Journal reported, citing people it didn’t identify.</p><p><blockquote>据《信报》援引未透露姓名的人士报道，奈雪的IPO零售部分超额认购超过400倍。</blockquote></p><p> The top-of-the-range pricing values the bubble tea chain at about $4.38 billion, up from the $2 billion in its last funding round. It originally planned to file for an IPO in the U.S. in February last year, Bloomberg News reported, but eventually opted for Hong Kong.</p><p><blockquote>顶级定价对这家珍珠奶茶连锁店的估值约为43.8亿美元，高于上一轮融资的20亿美元。据彭博社报道，该公司最初计划于去年2月在美国申请IPO，但最终选择了香港。</blockquote></p><p> The Shenzhen-based firm sells fresh-fruit teas, cold-brew beverages and baked goods. It recorded losses of 203 million yuan in 2020 and 40 million yuan in the previous year, according to its prospectus. Revenue rose 22% year-on-year to 3.1 billion yuan.</p><p><blockquote>这家总部位于深圳的公司销售鲜果茶、冷饮和烘焙食品。招股书显示，该公司2020年亏损2.03亿元，上年亏损4000万元。营收同比升22%至31亿元。</blockquote></p><p> Nayuki plans to use proceeds from the offering to expand its teahouse network, deepen market penetration and strengthen its supply chain. It had 491 flagship Nayuki outlets at the end of last year, including 489 in mainland China and one each in Hong Kong and Japan.</p><p><blockquote>奈雪计划将此次发行所得用于扩大其茶馆网络、深化市场渗透并加强其供应链。截至去年底，其拥有491家奈雪旗舰店，其中中国内地489家，香港和日本各1家。</blockquote></p><p> Nayuki’s shares are set to start trading in Hong Kong on June 30. JPMorgan Chase &amp; Co., CMB International Capital Ltd. and Huatai International Ltd. are joint sponsors for the listing.</p><p><blockquote>奈雪的股票定于6月30日在香港开始交易。摩根大通、招银国际金融有限公司及华泰国际有限公司为本次上市的联席保荐人。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://finance.yahoo.com/news/bubble-tea-chain-said-raise-111206490.html\">Bloomberg</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"02150":"奈雪的茶"},"source_url":"https://finance.yahoo.com/news/bubble-tea-chain-said-raise-111206490.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1178700711","content_text":"(Bloomberg) -- Chinese bubble tea chain Nayuki Holdings Ltd. has raised HK$5.09 billion ($656 million) after pricing its Hong Kong initial public offering at the top of a marketed range, the latest company to ride a resurgence of listings in the Asian financial hub.\nNayuki, whose popular fresh-fruit teas include cheese-foam-topped beverages, has priced 257.3 million shares at HK$19.8 each, according to terms of the deal obtained by Bloomberg News. It had marketed the shares at HK$17.2 to HK$19.8 apiece.\nThe teahouse operator is testing the waters after Angelalign Technology Inc., a maker of clear orthodontic braces, heralded a revival in Hong Kong’s IPO market with a massive 132% pop on its June 16 debut, becoming one of this year’s most popular offerings in the city.\nFirst-time share sales in Hong Kong are ticking up after a period of muted activity, as an easing of the global tech selloff has created a more favorable backdrop for debuts. At least 13 companies are currently in the lineup to go public, compared to only two deals priced in April and four in May, according to data compiled by Bloomberg.\nStill, not every IPO is getting a warm welcome as investors have become more selective amid higher volatility in markets and growing expectations of a tightening of U.S. monetary policy. China Youran Dairy Group Ltd. and CARsgen Therapeutics Holdings Ltd. slumped 12% and 9%, respectively, in their trading debuts last Friday.\nNayuki’s share sale attracted five cornerstone investors who agreed to subscribe for about $155 million of stock. They are UBS Asset Management, China Universal Asset Management, GF Fund, China Southern Asset Management and CCB International, according to the prospectus.\nThe retail portion of Nayuki’s IPO was more than 400 times oversubscribed, the Hong Kong Economic Journal reported, citing people it didn’t identify.\nThe top-of-the-range pricing values the bubble tea chain at about $4.38 billion, up from the $2 billion in its last funding round. It originally planned to file for an IPO in the U.S. in February last year, Bloomberg News reported, but eventually opted for Hong Kong.\nThe Shenzhen-based firm sells fresh-fruit teas, cold-brew beverages and baked goods. It recorded losses of 203 million yuan in 2020 and 40 million yuan in the previous year, according to its prospectus. Revenue rose 22% year-on-year to 3.1 billion yuan.\nNayuki plans to use proceeds from the offering to expand its teahouse network, deepen market penetration and strengthen its supply chain. It had 491 flagship Nayuki outlets at the end of last year, including 489 in mainland China and one each in Hong Kong and Japan.\nNayuki’s shares are set to start trading in Hong Kong on June 30. JPMorgan Chase & Co., CMB International Capital Ltd. and Huatai International Ltd. are joint sponsors for the listing.","news_type":1,"symbols_score_info":{"02150":0.9}},"isVote":1,"tweetType":1,"viewCount":1400,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":163327019,"gmtCreate":1623860210331,"gmtModify":1634026865490,"author":{"id":"3574940915326235","authorId":"3574940915326235","name":"TheMysTrader","avatar":"https://static.tigerbbs.com/08abc512620038ac153ab0bf62705216","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574940915326235","idStr":"3574940915326235"},"themes":[],"htmlText":"Wow[得意]&nbsp;","listText":"Wow[得意]&nbsp;","text":"Wow[得意]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/163327019","repostId":"2143978737","repostType":4,"isVote":1,"tweetType":1,"viewCount":1964,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":163328074,"gmtCreate":1623860099598,"gmtModify":1634026869600,"author":{"id":"3574940915326235","authorId":"3574940915326235","name":"TheMysTrader","avatar":"https://static.tigerbbs.com/08abc512620038ac153ab0bf62705216","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574940915326235","idStr":"3574940915326235"},"themes":[],"htmlText":"Interesting","listText":"Interesting","text":"Interesting","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/163328074","repostId":"2143978737","repostType":4,"isVote":1,"tweetType":1,"viewCount":1401,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}